,СЛОВО,Abstract:,Infections,in,childhood,play,an,essential,role,the,pathogenesis,of,cognitive,and,psycho-emotional,disorders.,One,possible,mechanisms,these,impairments,is,changes,functional,properties,NMDA,AMPA,glutamate,receptors,brain.,We,suggest,that,bacterial,infections,during,early,life,"period,",which,critical,for,excitatory,synapse,"maturation,",can,affect,subunit,composition,receptors.,In,present,"study,",we,investigated,effect,repetitive,lipopolysaccharide,(LPS),intraperitoneal,(i.p.),administration,(25 μg/kg/day,on,"P14,","16,","18),",mimicking,infectious,"disease,",expression,subunits,young,rats.,revealed,a,substantial,decrease,GluN2B,hippocampus,at,P23,using,Western,blot,analysis,real-time,polymerase,chain,reaction,assay.,Moderate,were,also,found,"GluN1,","GluN2A,",GluA1,mRNA,expression.,The,LPS-treated,rats,exhibited,decreased,exploratory,locomotor,activity,open,field,test,impairment,spatial,learning,Morris,water,maze.,Behavioral,accompanied,by,significant,reduction,long-term,hippocampal,synaptic,potentiation.,Our,data,indicate,LPS-treatment,period,maturation,alters,ionotropic,receptor,gene,"expression,",disturbs,"plasticity,","behavior.
",Prolonged,exposure,to,manganese,(Mn),may,lead,toxic,effects,central,nervous,system,(CNS).,underlying,neuronal,death,from,Mn,are,not,well,understood,but,undoubtedly,involve,inflammatory,processes.,aim,this,study,was,explore,long-lasting,intranasal,focusing,processes,catecholamine,"(dopamine,",norepinephrine),levels,striatum,hippocampus.,It,instillation,MnCl2,solution,once,day,90,days,leads,impaired,movement,gait.,observed,concentration,increased,(by,30,%),220,"%),",dopamine,(24,DOPAC,(35,reduced,"striatum,",(190,(220,with,simultaneously,norepinephrine,(30,Observation,cytokine,both,assayed,cytokines,(IL-1β,TNF-α),There,3-fold,increase,IBA-1,"mRNA,",2-fold,NFκB,dramatic,IkB,striatum.,Taken,"together,",high,dose,induces,neuroinﬂammation,neurotransmission,"disturbance,",specific,each,studied,brain,"region.
",Shortly,after,syphilis,appeared,Europe,time,Columbus’,voyage,New,"World,",big,"pox,",as,it,often,"known,",became,serious,issue,Russia,"diagnosis,","treatment,",prevention.,Members,Russian,royal,family,made,aware,disease,adolescence,onward.,Czar,Peter,Great,had,many,sexual,contacts,could,have,contracted,any,number,sexually,transmitted,diseases,(STDs),quite,common,his,era.,"Nevertheless,",contributions,analyzed,available,sources,contemporary,"doctors,",later,medical,"analyses,",reveal,no,evidence,he,or,other,STD.,Most,"likely,",died,acute,renal,failure,due,urinary,tract,"obstruction.
",Upper,respiratory,world's,most,disease.,etiologic,agents,behind,upper,(URTIs),"are,","fact,",diverse,set,pathogens,such,"influenza,","parainfluenza,","adenovirus,","rhinovirus,",others.,More,than,200,known,be,involved.,Differential,diagnosis,viral,sometimes,complicated,their,diversity,similarity,clinical,presentation.,This,work,devoted,development,method,enables,simultaneous,detection,six,URTI,pathogens:,IAV;,IBV;,RSV;,hAdV;,hPIV2;,hPIV3.,Antibody,microarray,technology,utilized,accomplish,analysis.,preparation,protein,microchip,"creation,","produced,","characterized,",selected,approximately,50,monoclonal,antibodies;,aforementioned,"pathogens,",optimal,antibody,pair,selected.,A,"created,",its,core,working,conditions,optimized.,With,balance,between,convenience,maximal,assay,sensitivity,"mind,",one-step,approach,developed,accomplishing,ELISA-like,“sandwich”,interaction,manufactured,(antibody,microarray).,Reference,strains,used,establish,lower,limits,(LoD),For,"IAV,",LoD,0.25 ng/ml,total,protein.,"viruses,",ranged,1,2 ng/ml,These,slightly,better,those,standard,"ELISA,",inferior,PCR.,"Overall,",believe,good,alternative,existing,"methods,",allowing,relatively,quick,"(overnight),","inexpensive,",screening,several,pathogens.,design,conducive,further,"development,",panel,expanded,include,"members.
",fullerene,"members,","C60,",has,potential,application,various,fields,biomedicine,including,reactive,oxygen,species,(ROS),scavenging,"activity,",inhibiting,tumours,inactivating,viruses,"bacteria,",elaboration,diagnostic,targeted,drug,delivery,tools.,"However,",hydrophobicity,molecule,impedes,practical,"use,",therefore,actuality,research,functionalisation,fullerenes,leading,amphiphilic,derivatives,remains,important.,"work,",water-soluble,carboxylated,derivative,C60[C(COOH)2]3,studied.,Extensive,biomedical,investigation,"compound,","namely,",binding,human,serum,albumin,"(HSA),",radical,diphenylpicrylhydrazyl,(DPPH),"radical,",photodynamic,"properties,",cytotoxicity,embryonic,kidney,(HEK293),cell,"line,",erythrocytes',"haemolysis,",platelet,"aggregation,",genotoxicity,peripheral,mononuclear,cells,(PBMC),conducted.,"Moreover,",dynamic,structural,characteristics,C60[C(COOH)2]3–H2O,binary,obtained,molecular,(MD),"method,",size,distribution,associates,"measured.
","Aims
",our,single-center,retrospective,evaluated,whether,level,different,checkpoint,molecules,bone,marrow,biopsies,course,patients,myelodysplastic,syndrome,"(MDS).
",Methods,"results
",consecutive,cohort,55,MDS,treated,center,2003,2018,technique,able,detect,following,antigens:,"PD-1,","PD-L1,","PD-L2,","LAG-3,","Gal-9,","TIM-3,",CD80.,association,3-year,overall,relapse-free,survival,time-to-progression,analyzed.,Intensive,TIM-3,100%,cases.,"Also,","cases,",moderate,Gal-9,observed.,follow-up,progression,seen,72.9%,CD80,52.1%,low,(p=0.04).,CTLA4,ligands,co-expressed,majority,patients.,General,ligand,associated,incidence,progression:,67.2%,"progressed,",while,group,only,33.3%,cases,(p=0.059).,"CD80,","TIM3,",blasts,risk,according,IPSS,IPSS-R,"scales.
","Conclusions
",preliminary,underlined,heterogeneous,immune,warrants,studies,define,heterogeneity,develop,treatment,"approaches.
","Background
",COVID-19,pandemic,broadly,disrupted,non-invasive,stimulation,(NIBS).,rapid,onset,societal,disruption,evolving,regulatory,restrictions,allowed,systematic,planning,how,continue,throughout,restarted,abated.,urgency,provide,NIBS,intervention,neurological,mental,health,"indications,",catalyst,fundamental,"research,",dampened,parallel,efforts,address,life-threatening,aspects,COVID-19;,rather,need,heightened,mitigate,consequences,related,"COVID-19.
","Objective
",To,facilitate,re-establishment,access,services,operations,current,future,"outbreaks,",discuss,framework,balancing,importance,safety,"considerations,",addressing,needs,all,stakeholders.,focus,Transcranial,Magnetic,Stimulation,(TMS),intensity,transcranial,Electrical,(tES),-,Direct,Current,(tDCS),Alternating,"(tACS).
","Methods
",consensus,paper,provides,guidelines,practices,managing,reopening,clinics,laboratories,through,immediate,ongoing,stages,COVID-19.,document,reflects,experts,domain-relevant,expertise,spanning,"technology,","services,",basic,–,international,perspective.,outline,"aspects,","resources,","optimization,",accommodations,"demographics.
","Results
",model,based,three,phases,(early,"impact,","practices,",preparation),11-step,checklist,(spanning,removing,streamlining,in-person,"protocols,",incorporating,"telemedicine,",COVID-19-associated,adverse,events),proposed.,Recommendations,implementing,social,distancing,sterilization,"equipment,",considerations,positive,populations,"comorbidities,",regarding,resource,era,outlined.,specifically,(sub-)populations,"pediatric,","stroke,","addiction,",elderly.,Numerous,case-examples,across,world,"described.
","Conclusion
","evident,","urgent,",maintain,"pandemic,",anticipating,waves,mind.,proposed,robust,structured,strategy,aims,anticipated,challenges,maintaining,scientific,rigor,"risk.
",Background:,Data,genetic,markers,determine,prognosis,multiple,sclerosis,(MS),still,limited.,galanin,polymorphism,rs948854,MS,been,demonstrated,earlier.,Objectives:,confirm,earlier,findings,distinct,previously,"patients,",characterized,one,candidates,stratification,MS.,Methods:,assess,rate,"progression,",severity,score,(MSSS),Age,Related,Multiple,Sclerosis,Severity,(ARMSS),"used,",along,Progression,Index,(PI).,Results:,minor,allele,"revealed,",confirming,findings.,An,proportion,MSSS > 5,(high,progression),among,G,carriers,(genotypes,AG,GG),compared,AA,genotype.,"Furthermore,",age,correlated,MSSS,value,late,(>30,years).,Conclusion:,"Collectively,",support,contribution,"MS.
","Summary
","Purpose
",describe,analyze,patient,recurrent,idiopathic,exudative,polymorphous,vitelliform,maculopathy,"(AEPVM),",followed,"detail,",propose,"algorithm.
","Design
",Retrospective,observational,"analysis.
","Patient
",adult,male,diagnosed,AEPVM,who,two,relapses,12-month,eight,years,initial,"onset.
",Review,"charts,",multimodal,"imaging,",electrophysiology,repeatedly,underwent,complete,ophthalmic,"examinations,",best-corrected,visual,acuity,testing,"(BCVA),",slit-lamp,fundus,examinations;,digital,"photography,",time-domain,optical,coherence,tomography,(OCT),2009,(Stratus,"OCT,",Carl,Zeiss,"Meditec,",USA),spectral-domain,OCT,2017–2018,"(Spectralis-OCT,",Heidelberg,"Engineering,","Germany),",together,autofluorescence,"(FAF),",fluorescein,angiography,"(FA),",indocyanine,green,"(ICGA),",HRA2,(Heidelberg,Germany);,microperimetry,(MP-1,"microperimeter,","Nidek,",Japan).,Laser,flare,photometry,(Kowa,"FM-600,",Japan),"performed.
",Main,outcome,"measures
",Clinical,features,"AEPVM,",algorithm,rare,"cases.
",Case,report,25-year-old,Caucasian,typical,serous,neuroepithelial,detachment,irregular,retinal,"elevations,",ophthalmoscopically,resembling,"folds,",subsequent,subretinal,accumulation,characteristic,yellow–white,deposits.,Features,case,rarely,"described,",even,yet,"reported,",indocyanine-,fluorescein-negative,intraretinal,cystic,"changes,",optic,disc,hyperfluorescence,"FA,",elevations,choroidal,"thickness,",lack,"recovery,",very,slow,anatomical,improvement,relapses.,Bimonthly,evaluation,SD-OCT,informative,demonstrating,evolution,pathological,"signs.
",chronic,condition,uncertain,outcomes.,variable,presentations,depending,stage,manifestations,imaging,pathologic,process,overlap.,Patients,should,occurs,"slowly,",if,all.,recommended,"ABSTRACT
",Allogeneic,hematopoietic,transplantation,(HCT),high-risk,T,lymphoblastic,leukemia,(T-ALL).,without,HLA-identical,"donor,",haploidentical,(haplo-),HCT,becoming,source,stem,donation.,scarce,predictive,factors,setting.,identified,122,adults,(20%,female;,median,"age,",31,years;,"range,",18,68,years),T-ALL,haplo-HCT,post-transplantation,cyclophosphamide,(ptCy),2010,2017.,duration,living,23,months.,2-year,incidences,relapse,nonrelapse,mortality,45%,"21%,",respectively.,leukemia-free,"(LFS),","(OS),",graft-versus-host,(GRFS),"34%,","42%,","27%,",LFS,OS,highly,influenced,status,"transplantation,",being,49%,"55%,","respectively,",first,remission,(CR1);,34%,"50%,",second,CR,(CR2);,8%,"12%,",active,On,multivariate,"analysis,",OS.,Transplantation,CR2,negatively,affected,"LFS,",whereas,"conclusion,",ptCy,produced,encouraging,results,challenging,particularly,when,performed,CR.,Despite,limitation,small,sample,"size,",type,"conditioning,",calling,into,question,body,irradiation-based,myeloablative,conditioning,"setting.
","HIV,",heavy,"drinking,",smoking,pro-inflammatory,coronary,heart,(CHD).,Interventions,reduce,alcohol,"smoking,",HIV-positive,people,"inflammation,",CHD,risk.,Varenicline,cytisine,proven,therapies,cessation,consumption.,comparative,efficacy,varenicline,consumption,"tested,",nor,effectiveness,reported,"smoking.
",describes,protocol,Studying,Partial,agonists,Ethanol,Tobacco,Elimination,Russians,HIV,(St,PETER,"HIV),",four-arm,parallel-group,randomized,controlled,trial,comparing,"varenicline,","cytisine,",nicotine,replacement,therapy,"(NRT).
",recruiting,four,hundred,drinking,smokers,interested,cutting,down,and/or,tobacco,St.,"Petersburg,",Russia.,Participants,randomly,assigned,receive,either,varenicline + NRT,"placebo,",placebo + active,"NRT,",cytisine + NRT,NRT.,All,participants,evidence-based,counseling,"medication,",placebo.,Outcomes,are:,1),%,past,month,(primary,months),craving;,2),cigarettes,per,3,7-day,point,prevalence,abstinence,and;,3),"risk,",St,addresses,paucity,guide,"smokers.
",Here,evaluate,mast,infection,influenza,A/H5N1,virus,immunized,mice.,CBA,mice,intramuscularly,formalin-inactivated,A/Vietnam/1194/2004,(H5N1)NIBRG-14,(H5N1).,Serum,samples,"7,","12,","14,",21,immunization.,At,infected,intranasally,A/Indonesia/5/2005,(H5N1)IDCDC-RG2,(H5N1),half,animals,receiving,mixture,antihistamines.,67%,vaccinated,protected,lethality,43%,PBS-immunized,group.,Administration,antihistamines,up,85%–95%.,Immunohistochemical,examination,CD117,staining,lungs,larger,quantity,activated,mock-immunized,histamine,blood.,experimental,involvement,they,produce,incomplete,formation,response,vaccination,mismatch,vaccine,"viruses.
",Gestational,methylazoxymethanol,acetate,(MAM),produces,offspring,phenotype,relevant,"schizophrenia,",positive-,negative-like,"symptoms,","deficits,",dopaminergic,"dysfunction,",abnormalities.,show,prenatally,MAM,gestational,17,display,D3,(D3),prefrontal,cortex,"(PFC),",nucleus,"accumbens,",D2,(D2),exclusively,PFC.,change,blood,perfusion,circle,Willis,"hippocampus,",paralleled,enlargement,lateral,"ventricles,",detected,magnetic,resonance,(MRI),techniques.,Peripubertal,non-euphoric,phytocannabinoid,cannabidiol,(30 mg/kg),postnatal,(PND),19,PND,39,reverse,exposed,rats:,i),up-regulation,(only,partially,prevented,haloperidol,0.6 mg/kg/day);,ii),regional,flow,Molecular,modelling,predicted,bind,preferentially,"receptor,",where,act,partial,agonist,conformation,"ionic-lock,",conserved,GPCRs.,"summary,",demonstrate,altered,model;,however,transcript,likely,suggesting,might,contribute,schizophrenia,symptoms,represent,unexplored,target,antipsychotic,"cannabidiol.
",timing,immunosuppressive,combination,(PTCY),transplant,(haplo-HSCT),standardized.,schedules,immunosuppression,haplo-HSCT,509,PTCY,+3,+4,tacrolimus,(group,1;,"n = 215),",cyclosporine,(CSA),mycophenolate,mofetil,(MMF),+5,2;,"n = 170),",CSA + MMF,0,3;,n = 124).,Compared,2,"groups,",younger,(median,46,P = .02),more,received,(77%;,P,<,.01),regimen,containing,"thiotepa,","fludarabine,",busulfan,(84%;,P<,.01).,"years,",44%,"1,",48%,"2,",59%,(P=,.15);,(LFS),"43%,","46%,",53%,.05);,refined,"disease-free,",(rGRFS),"33%,","39%,",36%,(P = .02).,grade,II-IV,GVHD,25%,39%,18%,(P<,.01);,"25%,",24%,.50);,"36%,","37%,",26%,.02);,"26%,","20%,",21%,.35).,start,+1,(hazard,ratio,"[HR],",.58;,P=,.02),improved,rGRFS,"(HR,",.62;,P = .02).,outcomes,PTCY.,administered,improves,"rGRFS.
",Immune,pivotal,synucleinopathy,Parkinson’s,(PD),mediated,neurotoxic,alpha-synuclein.,limited,another,dementia,Lewy,bodies,(DLB).,Recent,impairment.,aimed,estimate,plasma,profile,synucleinopathies,(PD,"(PDD),",DLB).,Plasma,(interferon-gamma,"(IFN-gamma),",interleukin,(IL)-4,"(IL-4),","IL-6,","IL-10,",tumor,necrosis,factor,alpha,"(TNF-alpha),",monocyte,chemoattractant,protein-1,(MCP-1)).,estimated,16,"DLB,","PDD,",28,PD,individuals,disorders,(controls),Luminex,array,system.,Cognitive,assessed,Mini–Mental,State,Examination,(MMSE).,TNF-alpha,IL-6,elevated,"(DLB,",PDD),controls,IL-10,PDD,(p < 0.05).,IFN-gamma,"(p < 0.001,","p = 0.026,",respectively),DLB,(p = 0.032).,"PD,",MCP-1,(p < 0.001).,same,"time,",differences,"TNF-alpha,",found.,pronounced,"demetia.
",Many,metastatic,non-small-cell,lung,cancer,(mNSCLC),experience,first-,second-line,treatment;,options,required,"ARCTIC,",phase,"III,","randomized,",open-label,durvalumab,±,tremelimumab,versus,care,(SoC),≥,third-line,"mNSCLC.
","methods
",ARCTIC,comprised,independent,sub-studies.,Study,A:,126,≥25%,(TCs),expressing,programmed,ligand-1,(PD-L1),(1,:,[up,12,months,10 mg/kg,every,weeks,(q2w)],SoC.,B:,469,PD-L1,TC,<25%,(3 :,durvalumab +,(12,20,mg/kg +,mg/kg,q4w,then,34,10,"q2w),","SoC,",(up,24,q12w).,Primary,end,points:,(OS),progression-free,(PFS),SoC,(study,A;,descriptive,only),"B).
",11.7,(durvalumab),6.8,{hazard,(HR),0.63,[95%,confidence,interval,"(CI),",0.42–0.93]};,PFS,3.8,2.2,[HR,0.71,(95%,"CI,",0.49–1.04)].,11.5,(durvalumab +,tremelimumab),8.7,0.80,0.61–1.05);,P =,0.109].,Median,3.5,groups,0.77,0.59–1.01);,0.056].,Treatment-related,3/4,events:,9.7%,44.4%,(SoC;,A),22.0%,36.4%,heavily,pretreated,"mNSCLC,",clinically,meaningful,improvements,(patients,≥25%);,numerical,<25%).,Safety,profiles,consistent,previous,"studies.
",Trial,"registration
",Clinicaltrials.gov,identifier:,"NCT02352948.
","Objectives
",Because,reference,intervals,(RIs),biochemistry,analytes,matched,population,"defined,",joined,global,values,(RVs),coordinated,IFCC,Committee,Intervals,Decision,Limits,"(C-RIDL).
",According,C-RIDL,harmonized,"protocol,",793,healthy,volunteers,recruited,"Saint-Petersburg,","Moscow,",Yekaterinburg.,tested,analytes.,Sources,variation,RVs,explored,regression,partitioning,sex,judged,deviation,ANOVA.,Latent,abnormal,exclusion,(LAVE),applied,influence,metabolic,inappropriate,sampling,conditions.,RIs,computed,parametric,"method.
",No,appreciable,between-city,Partition,Age-related,"analytes,",especially,females.,trend,exaggerated,nutritional,closely,mass,index,"(BMI),",because,BMI,increases,prominently,age.,"Therefore,",BMI > 28 kg/m2,excluded,determining,age-specific,RIs.,LAVE,effective,lowering,"markers.
",established,biochemical,up-to-date,methods,detailed,consideration,RVs.,similar,participating,"countries.
",Adequate,transplacental,passage,maternal,thyroid,hormone,important,normal,fetal,growth,development.,Maternal,overt,hypothyroidism,hyperthyroidism,"birthweight,",knowledge,gaps,remain,subclinical,function,abnormalities,birthweight—both,general,third,trimester,pregnancy.,examine,associations,"birthweight.
",review,individual-participant,"meta-analysis,",searched,MEDLINE,"(Ovid),","Embase,",Web,"Science,",Cochrane,Central,Register,Controlled,"Trials,",Google,Scholar,inception,Oct,"15,","2019,",prospective,pregnancy,issued,invitations,identify,authors,join,Consortium,Thyroid,Pregnancy.,"pregnancies,",in-vitro,"fertilisation,",pre-existing,medication,"usage,","miscarriages,",stillbirths.,main,(SGA),"neonates,",large,newborn,birthweight.,analysed,mixed-effects,models,adjusting,"BMI,","ethnicity,","parity,","sampling,","sex,",birth.,pre-registered,International,Prospective,Systematic,"Reviews,","CRD42016043496.
","Findings
",2526,published,"reports,",36,cohorts,met,inclusion,criteria.,15,agreed,"participate,",five,unpublished,datasets,"added,",giving,48 145,mother–child,pairs,"exclusions,",whom,1275,(3·1%),(increased,stimulating,[TSH],free,thyroxine,[FT4]),929,(2·2%),isolated,hypothyroxinaemia,(decreased,FT4,TSH).,higher,SGA,euthyroidism,(11·8%,vs,10·0%;,adjusted,difference,"2·43%,",95%,CI,0·43,4·81;,odds,[OR],"1·24,",1·04,1·48;,p=0·015),mean,birthweight,(mean,−38,"g,",−61,−15;,"p=0·0015),",measurement,second.,Isolated,(7·3%,"10·0%,","−2·91,",−4·49,−0·88;,OR,"0·70,",0·55,0·91;,p=0·0073),45,73;,p=0·0012).,Each,SD,TSH,6,g,(–10,−2;,"p=0·0030),",estimates,women,peroxidase,negative,(pinteraction=0·10).,(–25,−17;,"p<0·0001),","second.
","Interpretation
","inverse,",dose-response,(even,within,range),advance,understanding,complex,relationships,"outcomes,",prompt,careful,risks,benefits,levothyroxine,"pregnancy.
","Funding
",Netherlands,Organization,Scientific,Research,(grant,"401.16.020).
",Lorlatinib,third-generation,tyrosine-kinases,inhibitor,(TKI),targeting,ALK/ROS1,fusions.,FDA,approved,lorlatinib,TKI-pretreated,ALK(+),"NSCLC,",approval,ROS1(+),pending.,largest,real-world,NSCLC,harboring,rearrangements,"lorlatinib.
",123,enrolled,retrospectively,(data,cut-off,1/1/2019).,program,therapy.,Outcome,defined,investigator,upon,RECIST,1.1,"criteria.
",106,8,countries.,included,"males,",73,never-smokers,metastases.,Extracranial,(EC),intracranial,(IC),rates,(RR),60,62,"%,",control,(DCR),91,88,Mean,(DoT),23.9 ± 1.6,(mOS),89.1 ± 19.6,ROS1,53,65,EC,IC,RR,67,DCR,92,78,DoT,18.1 ± 2.5,mOS,90.3 ± 24.4,significantly,line,parameters.,events,edema,(48,hyperlipidemia,(47,weight,gain,(25,fatigue,%).,CNS,1–2,"patients.
",shows,outstanding,EC/IC,ALK/ROS1(+),NSCLC.,89 ± 19,supports,90 ± 24,unprecedented,"NSCLC.
",Diabetes,mellitus,dysregulation,complications.,50%,diabetes,suffer,diabetic,"polyneuropathy,",involves,presence,nerve,dysfunction,symptoms.,new,synthetic,arginine-rich,exendin-4,(Peptide,D),complications,caused,"diabetes,","neuropathy,",induced,administering,streptozotocin,(STZ).,Three,Peptide,D,"(0.1,",10 μg/kg).,Byetta®,(1 μg/kg),80,days.,Neuropathic,pain,tactile,allodynia.,STZ-treated,showed,allodynia,unlike,naïve,animals.,histological,diameter,sciatic,fibers,smaller,IHC,myelin,(MBP),Byetta®.,resulted,MBP,myelinated,fibers.,poly-arginine,peptides,promising,"polyneuropathies.
",pattern,auditory,preterm,children,"birth.
","design
",longitudinal,"study.
",involved,271,aged,old.,Children,divided,groups:,70,birth,32–36,(Group,201,22–31,2).,Hearing,"ABR,","ASSR,","OAE,",behavioral,"audiometry,",pure,tone,audiometry.,"Additionally,",some,"children,","CT,","MRI,",GBJ2,evaluations,performed.,Assessments,hearing,3–4,times,year,under,age;,2–3,5,over,Infants,problems,examined,"life,",annual,examinations,"aged.
",SNHL,ANSD,(25.7%),64,(31.8%),Group,occurrence,assessment,(p > 0.05).,Further,children:,child,1.,Four,kinds,noted:,recovery,ANSD;,loss;,transformation,"SNHL,",vice,versa.,"factors,",discussed,"article.
",prematurely,born,tends,"unstable,","infants,",deteriorate,improve.,before,weeks’,gestation,require,least,until,Caution,advised,cochlear,implantation,32,"age.
","Introduction
","II,",single-arm,ASCEND-3,ceritinib,anaplastic,lymphoma,kinase,(ALK),(ALKi)–naive,ALK-rearranged,lines,chemotherapy.,"Here,",final,"results.
",Eligible,(including,asymptomatic,neurologically,stable,metastases),oral,(750,"mg/day,",fasted).,primary,investigator-assessed,(ORR).,Secondary,points,Blinded,Independent,Committee–assessed,ORR;,investigator-,"rate,","response,",(PFS);,(OS);,safety.,Exploratory,patient-reported,"outcomes.
",Of,124,"enrolled,",(98.4%),antineoplastic,medications,(31,[25.0%],"regimens),",49,(39.5%),baseline,cutoff:,January,"22,",2018),52.1,"(range,",48.4–60.1),ORR,67.7%,[CI]:,"58.8–75.9),",16.6,CI:,11.0–23.2).,51.3,42.7–55.3).,(all,"grades,",≥60%,all-causality),diarrhea,"(85.5%),",nausea,"(78.2%),",vomiting,(71.8%).,(14.5%),event,discontinuation.,Health-related,quality,maintained,"treatment.
",Ceritinib,prolonged,"OS,","PFS,",chemotherapy-pretreated,(at,"lines),",ALKi-naive,ALK+,possibilities,angioprotection,osteonecrosis,given,bisphosphonates.,"experiment,",27,injected,saline;,zoledronic,acid,weeks;,"weeks,",added,doses,sulodexide,weeks.,After,constructed,teeth,extracted.,velocity,linear,periodontal,area,extracted,tooth,laser,high-frequency,Doppler,ultrasound,(with,vasoactive,substance,acetylcholine,3%,1min).,structure,bony,tissues,head,"tomography,",saline,microcirculation,use,acid.,mucous,membranes,"and,",greater,"extent,",tissue.,Zoledronic,causes,periosteal,"disorders,",includes,cellular,component,(impaired,endothelium-dependent,vasodilation,membrane,vessels),reducing,tissues.,"Sulodexide,","however,",restoration,reduces,"osteonecrosis.
",subcortical,pathways,motor,spinal,cord,injury,(SCI),animal,models.,descending,interlimb,lumbosacral,excitability,SCI,"humans.
",Ulnar,transcutaneous,electrical,condition-test,paradigm,connections,linking,cervical,segments,non-injured,(n=15),injured,(n=18),"participants.
",Potentiation,spinally,evoked,responses,(sEMRs),ulnar,7/7,volitional,leg,muscle,"activation,",6/11,activation.,"six,",sEMRs,rostral,innervation,entry,"zones.
",Descending,modulation,pools,via,projections,exist,despite,absence,"activation.
","Significance
",Evaluation,"sub-clinical,",spared,residual,"function,",plasticity,"rehabilitation..
",Macrophages,participate,regulation,morphogenetic,placenta.,roles,unclear,placental,macrophages,(Hofbauer,cells).,characterize,steps,production,(intracellular,synthesis,secretion),compare,secretory,villous,"tissue.
",tissue,placentas,pregnancies,9–12,38–40,gestation.,Intracellular,determined,cytometry,antibodies.,Secreted,quantified,cytometric,bead,"ELISA.
",Two,patterns,macrophages.,Cytokines,"(IL-1,","IL-8,",TNFα),basal,stimulated,endotoxin.,"(IL-11,","IL-17A,","IL-17F,","TGF-β,",VEGF),constitutive,did,respond,stimulation.,age-dependent,observed:,secretion,TNFα,IL-8,IL-11,IL-17,third-trimester,first-trimester,cells.,Comparison,suggested,intraplacental,extraplacental,"production.
","Discussion
",would,safe,assume,"production,",correspond,macrophages:,“immune”,“morphogenetic”.,attenuated,supposedly,local,"levels,",confined,Mutations,glucocerebrosidase,(GBA),cause,Gaucher,"(GD),",lysosomal,storage,disorder,"(LSD),",Parkinson's,(PD).,Lysosome,functionality,plays,extracellular,vesicles,(EVs),content.,EVs,GD,terms,"amounts,","distribution,",cargo.,sequential,centrifugation,сryo-electron,microscopy,"(cryo-EM),",nanoparticle,tracking,"(NTA),",light,scattering,(DLS).,exosomal,HSP70,tetrasponins,cytometry.,Protein,profiling,mass-spectrometry,(shotgun,analysis).,morphology,exosomes,derived,cryo-EM,DLS,"(р<0.0001,","p < 0.001,",confirmed,mode,NTA,(p < 0.02).,Cryo-EM,double,multilayer,enriched,surface,"(CD9,","СD63,",CD81),exosome-associated,Proteomic,proteins,pathogenesis.,"Thus,",striking,alteration,"morphology.
",perform,postural,neuropsychiatric,tremor,"(ET),","phenotypes,",combined,ET,"(ET-PD).
",169,(1.0–2.0),111,advanced,(2.5–3.0),Hoehn,Yahr,"scale,",26,ET-PD,study.,Motor,non-motor,standardized,scales,"stabilometry.
",ETPD,milder,parkinsonism,posture,walking,scales.,"ETPD,",PD.,Using,"stabilometry,",discovered,indexes,stabilometric,parameters,although,"ET.
",conducted,helpful,differential,diagnosis.,helps,expand,"ET-PD.
",recent,highlighted,autophagy,pathway,(ALP),Genes,GBA,"LRRK2,",harbor,mutations,ALP.,"α-synuclein,",encoded,SNCA,"gene,",degraded,mainly,"ALP,",mutations/multiplications,chaperone,ALP,functions.,PD-related,"genes,","PRKN,","PINK1,","TMEM175,","SMPD1,","CTSD,",CTSB,"more,",Understanding,relationship,crucial,uncovering,long-awaited,neuroprotective,therapies.,"review,",will,"(other,",atypical,forms,"Parkinsonism,",review).,genes,"proteins,","PD.
",elucidate,dynamical,complexity,impulse,sensory,neurons,emergence,antinociceptive,painful,stimulus.,solve,problem,bifurcation,enabled,us,relations,nociceptive,neuron,effect.,shown,mechanism,suppression,ectopic,bursting,discharges,base,neurons.,Under,potassium,"blocking,",connected,entirely,modification,activation,gating,NaV1.8,sodium,channels,action,comenic,non-opioid,analgesic,anoceptin.,explain,neuropathic,"pain.
",Metoclopramide,widely,abortive,migraine,advantage,having,"antiemetic,",properties.,metoclopramide,"migraine,",anti-cephalalgic,elucidated.,Taking,account,key,trigeminovascular,"pathophysiology,",investigate,neurogenic,dural,valid,electrophysiological,neurovascular,nociception.,Extracellular,recordings,second-order,dura-sensitive,trigeminocervical,(TCC),anaesthetised,Cumulative,infusion,(three,30 min,"intervals,",5 mg/kg,i.v.,"step,",n = 8),dose-dependently,suppressed,firing,TCC,"stimulation,",maximally,30%[0–49%],(median[Q1-Q3]),4%[0–30%],"level,",respectively,(both,"p = 0.001,",(n = 8)).,By,"contrast,",separate,cumulative,(5 mg/kg,n = 6),vehicle,(n = 6),p > 0.05).,unable,does,suppress,anti-migraine,action.,here,neurophysiological,therapeutic,"migraine.
",Exposure,lipopolysaccharidein,affects,disturbances,potentiation,functions,"rats,
",Intranasal,disrupts,metabolism,"hippocampus,
","diseases,
",immunoassay,"pathogens,
",Biological,dynamics,simulation,"C60[C(COOH)2]3,
",checkpoints,predictor,"syndrome,
",Guidelines,TMS/tES,"pandemic,
",sclerosis:,"onset,
",Eight-year,"maculopathy,
",Haploidentical,Post-Transplantation,Cyclophosphamide,Cell,Acute,Lymphoblastic,Leukemia:,Report,European,Society,Blood,Marrow,Leukemia,Working,"Party,
",Design,drinkers,daily,"Russia,
",Mast,degranulation,release,influenza-sensitized,"mice,
",Altered,reversed,peripubertal,"treatment,
",Timing,Transplantation:,Comparative,Behalf,Party,"Transplantation,
",synucleinophaties,"dementia,
",ARCTIC:,"cancer☆,
",Establishing,major,population:,part,"values,
",Association,birthweight:,"meta-analysis,
",GLASS:,Global,Study:,real,"patients,
",Therapeutic,exenatide,neuropathy,Changes,premature,"study,
",Final,Overall,Survival,Other,Efficacy,Results,From,ASCEND-3:,Phase,II,of Ceritinib,ALKi-Naive,ALK-Rearranged,"NSCLC,
",Disorders,bisphosphonate,osteonecrosis:,Interlimb,"injury,
","macrophages,
","disease,
",Postural,instability,disturbance,overlapping,"Disease,
",Autophagy,disease;,"genetics,
",Mechanisms,"emergence,
",Influence,Trigeminovascular,Nociception:,Possible,Anti-migraine,Mechanism,"Action,
",Lysosomal,integral,protein-2,"(LIMP-2),",SCARB2,enzyme.,rs6812193,rs68250047,"studies,",genome-wide,studies.,rs8475,genotyped,604,(65,(fPD),539,history,(sPD)),413,(PD-GBA),mutation,(GBA-Carriers).,measured,PCR,CD45+,groups.,linkage,disequilibrium,population.,Increased,TT,variant,(OR,=,2.02;,p,0.001),sPD,fPD.,(AAO),GBA-PD,GBA-Carriers,(padjusted,"0.02,",padjusted,"0.003,",0.013),controls.,modified,rs8475.,status.,modifier,AAO,do,"status.
","Buspirone,","5-HT1aR,",useful,abdominal,IBS,Pain-related,buspirone,"5-HT1aRs,",located,tractus,solitarius.,5-HT1aR,transmission,NTS,unclear.,objective,NTS.,urethane-anesthetized,"rats,",types,pain-related,responding,noxious,colorectal,distension,(CRD),inhibitory,sustained,revealed.,Buspirone,"(1.0–4.0 mg kg−1,",iv),time-,dose-depended,CRD-induced,responses.,inhibits,inverts,4.0,"buspirone,",attenuates.,CRD-evoked,completely,blocked,intra-cerebroventricular,"WAY100,635.",agonist.,supraspinal,5-HT1a,dependents,anti-,pronociceptive,MicroRNA,(miRNAs),artery,"(CAD).
",expressions,myocardial,"miRNA-27а,","miRNA-133а,",miRNA-203,CAD,"Method
",cross-sectional,100,subjects,(60.9 ± 1.0 years;,men).,right,atrial,"miRNA-27a,",miRNA,"-133a,",referred,elective,bypass,graft,surgery,(CABG),scheduled,valve,"reaction.
",correlation,SYNTAX,I,(r = 0.693;,p < .001).,≥3,lesions,vessel,myocardium,(miRNA-27a:,234.62 ± 29.51,vs.,182.39 ± 19.62,relative,unit,(REU);,miRNA-133а:,127.53 ± 13.41,111.35 ± 12.31,REU;,miRNA-203:,5.25 ± 0.96,4.71 ± 0.67,р < 0.05);,11.41 ± 3.85,4.82 ± 1.82,8.42 ± 2.43,4.35 ± 1.23,145.71 ± 15.73,43.70 ± 9.67,р < 0.05).,decision,tree,multivessel,five-fold,>101.00,REU,"(OR,",5.90;,2.34–9.46;,"p < .001).
",Both,CABG,non-CAD,subjects.,corresponds,strongly,extent,"atherosclerosis.
",series,binuclear,PdII,carbene,complexes,synthesized,cis-[PdCl2(CNXyl)2],(1),"benzo-1,3-thiazol-2-amines",(2–6),structurally,characterized.,"regioisomers,",interconvert.,regioisomerization,diaminocarbene,first-order,"reaction,","is,","intramolecularly,",Hammett,function.,Electron-withdrawing,substituents,benzothiazole,moiety,increasing,solvent,polarity,accelerate,reaction.,donor,strength,correlates,less,isomerization,rates.,Based,interchange/dissociative,type.,kinetic,spectrometric,conclusion,rate-determining,step,breaking,carbon–nitrogen,bond,fragment,"complex.
",Type,(T2DM),ranks,top,worldwide.,T2DM,vascular,endothelial,dysfunction.,vessels,endothelium-derived,imbalance.,morphological,greatly,occurring,T2DM.,bed,"T2DM.
",Male,Wistar,fed,high-fat,diet,"20 weeks,",single,injection,(20 mg/kg).,glucose,tolerance,"test.
",Key,"findings
",dose-dependent,contraction,third-order,mesenteric,arterioles,serotonin,phenylephrine.,acetylcholine-dependent,relaxation,guanylate,cyclase,femoral,arteries,tendency,relaxation.,bioavailable,nitric,oxide,endothelin-1,"ROS.
","knowledge,",conjunction,"course,",allow,approaches,prevention,"disease.
",novel,potent,ALK,"inhibitor,",few,reporting,"use.
",35,non-small,"rearrangements,","(n = 5),",(n = 26),none,(n = 4),prior,tyrosine,inhibitors,compassionate,"program.
",Objective,(OR),(DC),registered,15/35,(43%),33/35,(94%),respectively;,metastases,responsive,(OR:,22/27,(81%);,DC:,27/27,(100%)).,21.8,"months,",approached,70.1,Only,4,out,experienced,effects;,them,benefit,lorlatinib.,no-adverse-events,users,strikingly,remaining,(1.1,23.7,10.5,"reached,",0.0001,comparisons).,translocation,variants,patients;,there,statistical,V.1,V.3,regard,"PFS.
",Use,excellent,caution,must,taken,experiencing,"drug.
",bariatric,interventions,infarct,rat,(T2DM).,no-reflow,phenomenon,Rats,"surgery,","sham-operated,",ileal,"transposition,",Roux-en-Y,gastric,"bypass,",sleeve,gastrectomy.,Oral,"tolerance,",glucagon-like,"peptide-1,",insulin,measured.,Six,subjected,ischemia-reperfusion,histochemical,determination,"(IS),","zone,",stasis,size.,Vascular,wire,"myography.
",reductions,compensation.,normalized,peptide-1,IS,Bariatric,provided,additional,alone.,surgeries,T2DM-induced,enhanced,contractile,5-hydroxytryptamine.,Sleeve,gastrectomy,synthase,vasodilatation,zone,infarct-limiting,"effect,",augmented,contractility,beneficial,cardiovascular,"diseases.
",investigates,event-related,oscillations,motion-onset,(MOR),sounds,moving,velocities.,EEG,recorded,stationary,sound,motion,interaural,differences.,MOR,"potential,",spectral,perturbation,(ERSP),inter-trial,(ITC),calculated,time-frequency,decomposition,signals.,similarly,magnitude,cN1,cP2,components,response.,delta-to-alpha,power,remained,"to,","including,",highest,"velocity,",gradual,induce,non-coherent,activity.,"Conversely,",abrupt,displacement,theta-alpha,consistency.,generated,resetting,"oscillations,",degree,considered,indicator,"processing.
",currently,thought,full,glycogen,(β-particle),spherical,shape,concentric,tiers,residues,glycogenin,about,42,nm.,β-particle,poorly,understood.,β-particles,hepatocytes,starved,situ,cytofluorometry,speed,Schiff's,reagent.,measurements,quickly,"stained,",labile,fraction,(LF),represents,internal,"molecule,",slowly,(SF),external,proteins.,predicts,3rd,4th,(42%,all),bound,7th,8th,~19%,tier,never,enzyme,amount,particle,variable.,makes,obtain,particular,"cell.
",Background,"Eculizumab,",terminal,complement,placebo,anti-aquaporin-4,immunoglobulin,G-positive,(AQP4+),neuromyelitis,optica,spectrum,(NMOSD),PREVENT,trial.,analyses,Asian,extension,(OLE).,"double-blind,",AQP4+,NMOSD,(2:1),intravenous,eculizumab,(maintenance,"dose,",1200 mg/2,weeks),completed,OLE.,Analyses,prespecified,subgroup,143,52,(36.4%),"(eculizumab,",n = 37;,n = 15);,(86.5%),concomitant,During,"PREVENT,",adjudicated,occurred,"ratio,",0.05;,interval:,0.01–0.35;,p = 0.0002).,95.2%,144,treatment.,"infections,","headache,",nasopharyngitis,subgroup.,Conclusion,Eculizumab,"NMOSD,",benefit–risk,registration,ClinicalTrials.gov,identifiers:,NCT01892345,(PREVENT);,NCT02003144,(open-label,"extension).
",task,synchronization,intermittent,photic,arterial,hypertension,manifestations.,recurrence,"index,",instantaneous,"frequencies,",synchrosqueezed,wavelet,transform,series.,synchronization.,manifested,photostimulation,bioelectric,"brain,",shift,frequency,range,excitation,frequency.,"origin.
",Migraine,sensitisation,mechanical,hyperalgesia,mechanotransduction,attack,unknown.,ion,channel,Piezo1,"involved,",since,expressed,trigeminal,ganglion,"neurons,","thus,",took,relay,centre,"pathway,",directly,impact,differently,Yoda1,processing,level.,facilitated,contributed,intravital,"microscopy,",dilation,meningeal,innervated,afferents.,selective,mechanosensitive,"channels,",favour,underlie,"Yoda1.
",Silica,silicon,"dioxide,","which,",amorphous,varying,"area,",pore,volume,"result,",physicochemical,sorption,characteristics.,silanol,silicas,possibility,functionalisation.,"addition,",Aerosil,allows,composites,content,biologically,substances.,biocompatibility,composite,380,"C60[C(COOH)2]3,",namely:,haemolysis,(spontaneous,"photoinduced),","HSA,",cyto-,"genotoxicity,",antiradical,Interest,creation,nanomaterial,fact,applications,"biomedicine,",ability,"species,",inhibition,tumour,inactivation,bacteria.,immobilisation,drugs,"theranostics.
",TNF-α,cytokine.,regions,carotid,"bodies,",organs,monitoring,O2.,hypothesised,circulating,(TNF)-α,ventilation,modulate,hypoxic,ventilatory,cyclooxygenase,(COX),(NOS),pathways.,pretreatment,diclofenac,L-NG-nitro,arginine,methyl,ester,(L-NAME),nonspecific,COX,"NOS,",rebreathing,normoxia,hypoxia.,Pretreatment,TNF-α.,NOS-related,“cross-talk”,mediates,underlies,inflammation,"function.
",HLA-haploidentical,(haplo-HCT),post-transplantation-cyclophosphamide,(PT-Cy),feasible,procedure,malignancies.,Haplo-HCT,PT-Cy,(ALL),lacking.,180,ALL.,9,2.7,years.,Disease,CR1,"24%,","45%,",CR+3,19%.,+4.,Bone,(BM),115,(64%).,42-day,engraftment,88.9%.,day-100,(GVHD),"28%,",21.9%.,(NRM),19.6%.,41.9%,CR1.,Estimated,"65%,","44%,",18.8%,transplanted,"CR1,","CR2,",CR3+,multivariable,(CR2,[hazard,{HR} = 2.19;,"P = .04]),",older,13,(HR = 2.07;,P = .03),(PBSC),(HR = 1.98;,P = .04),survival.,PBSC,NRM,(HR = 3.13;,P = .04).,option,"ALL,",namely,CR2.,BM,"survival.
",profound,people.,Concerns,"that,","extreme,",manifest,suicide,around,"world.
",sourced,countries,areas,internet,search,recourse,networks,literature.,Between,Sept,Nov,"2020,",official,websites,countries’,ministries,"health,",police,"agencies,",government-run,statistics,agencies,"equivalents,",translated,“suicide”,“cause,"death”,",broadening,attempt,public,sources.,country,came,government,monthly,Jan,July,"31,",2020.,searches,restricted,million,residents,pragmatic,"reasons,",relaxed,rule,literature,networks.,Areas,million.,interrupted,time-series,suicides,(from,March,2020),"country,",expected,April,"analysis).
",(16,high-income,upper-middle-income,"countries),",whole-country,ten,11,countries).,Rate,ratios,(RRs),CIs,numbers,began,area.,areas:,South,"Wales,",Australia,(RR,0·81,0·72–0·91]);,"Alberta,",Canada,(0·80,[0·68–0·93]);,British,"Columbia,",(0·76,[0·66–0·87]);,Chile,(0·85,[0·78–0·94]);,"Leipzig,",Germany,(0·49,[0·32–0·74]);,Japan,(0·94,[0·91–0·96]);,Zealand,(0·79,[0·68–0·91]);,Korea,[0·92–0·97]);,"California,",USA,(0·90,[0·85–0·95]);,Illinois,(Cook,"County),",[0·67–0·93]);,Texas,(four,"counties),",(0·82,[0·68–0·98]);,Ecuador,(0·74,"[0·67–0·82]).
",context,"countries,",largely,unchanged,declined,pre-pandemic,period.,vigilant,poised,situation,longer-term,economic,"unfold.
","None.
",inject,(PWID),stigma,utilization,health.,help,cope,intersectional,"care,",adapted,coping,"population.
",conduct,(RCT),‘Stigma,Coping,Reduce,Improve,Prevention,Treatment’,(SCRIPT),"intervention,","community-based,",form,Acceptance,Commitment,Therapy,"(ACT),",PWID,"Russia.
",civil,society,organizations,(CSO),delivering,harm,2:1,ACT,sessions,format,usual,CSO,care),psychological,flexibility,handle,stigma-related,"expectations,",emotions,experiences.,satisfaction,"scores.
",Stigma,outside,formal,settings,confront,negativities,lives,originating,stigma's,"barrier.
",encoding,(GCase),(GD),commonly,Parkinson,Ambroxol,pharmacological,chaperones,GCase.,Fourteen,"(GBA-PD),",thirty,enrolled.,GCase,hexosylsphingosine,(HexSph),dried,macrophage,spots,liquid,chromatography,coupled,tandem,spectrometry.,ambroxol,lysosomes,confocal,microscopy.,cultured,monocytic,3.3-fold),3.5-fold),untreated,(p < 0.0001,"p < 0.0001,",cultivation.,HexSph,2.1-fold),1.6-fold),respectively).,colocalization,marker,LAMP2.,modes,mutant,carrying,N370S,amino,substitution,pH,4.7,docking,simulations.,position,minimal,energy,close,vicinity,"residue,",370.,PBMC-derived,assessing,Rationale,&,Hemodialysis,(HD),"availability,","accessibility,","affordability,",HD,"worldwide.
","survey.
",Setting,"Participants
",Stakeholders,"(clinicians,",policy,"makers,",consumer,representatives),182,convened,Nephrology,"September 2018.
","Outcomes
","Use,","care.
",Analytical,"Approach
",Descriptive,"statistics.
",representatives,160,(88%),participated.,country-specific,maintenance,298.4,"(IQR,",80.5-599.4),(pmp).,incident,98.0,81.5-140.8),pmp,centers,4.5,1.2–9.9),pmp.,(3-4,hours,weekly),generally,27%,low-income,Home,32%,outcomes;,"61%, monitoring",small-solute,clearance;,"60%, monitoring",mineral,markers;,"51%, monitoring",survival;,"60%,",initiation,"dialysis,",5%,arteriovenous,almost,education,"suboptimal,",funding,procedures,"uniform,",copayments,income.,23%,pay,>75%,costs,4%,"Limitations
",survey,"bias,",desirability,collection,preventing,in-depth,variations,"quality,",affordability,"worldwide,",lowest,evident,low-,lower-middle–income,refractory,induction,chemotherapy,immunotherapy,dismal.,Salvage,allogeneic,(HSCT),10%,15%,cured,procedure.,Preclinical,bendamustine,(PTB),prophylaxis,graft-versus-leukemia,(GVL),PTB,antileukemic,HSCT,prophylaxis.,"(NCT02799147),","140,","100,",mg/m2,Myeloablative,fludarabine,single-agent,"PTB,",(MMF).,Inclusion,criteria,myelogenous,(AML),≥5%,clonal,marrow.,22,AML,Seven,140,(due,stopping,"rule),",documented,41%,secondary,59%.,blast,count,6%,97%).,sibling,mismatched,unrelated,7.,Engraftment,93%,89%,63%,measurable,"prophylaxis,",unusual,"complication,","(CRS),",70%,CRS,44%.,frequent,fever,liver,tests,"67%,",pancreatitis,"63%,",skin,vasculitis,"56%,",enterocolitis,"48%,",mucosa,disseminated,intravascular,coagulation,toxicity,26%.,HLA-mismatched,(75%,20%;,P = .0043).,Classic,Grade,(67%,25%;,P = .031).,severe,100-day,survivors,(100%,18%;,P = .002).,Three-year,28%,"[CI],",13%,"46%),",event-free,29%,46%).,Nonrelapse,46%,"64%),",11%,44%).,+100.,statistically,(P = .3481);,ALL,(35%,0%;,P = .0157).,augment,GVL,AML;,CRS-associated,necessitates,complication.,routine,cannot,recommended.,Combination,MMF,ameliorates,"complications,",setting,HLA-matched,allografts.,"elucidation.
",Previous,(SCZ),deficits,"processing,",contrast,processing.,brain-derived,neurotropic,(BDNF),measure,neuroplasticity,like,perception.,BDNF,first-episode,SCZ,Thirty-nine,43,Contrast,"low,",mid-,frequencies.,First-episode,except,middle,Negative,correlations,"BDNF,","variables,",mostly,frequencies,(i),alterations,magno-,parvocellular,functioning,(ii),highlights,biomarkers,measures,"disorders.
",5-year,disease-free,(bDFS),prostate,pencil,beam,scanning,(PBS),proton,radiation,"therapy.
","Materials
",2013,"2016,",284,modulated,"(IMPT),",ultrahypofractionated,schedule,(36.25,GyE,fractions).,Five,immediately,lost,thus,279,prospectively,collected,56.5,3.4-87.5),64.5,(40.1-85.7),prostate-specific,antigen,(PSA),6.35,μg/L,(0.67-17.3,μg/L).,121,(43.4%),"low-risk,",125,(44.8%),"favorable,",33,(11.8%),unfavorable,intermediate-risk,cancer.,(17.6%),neoadjuvant,hormonal,"therapy,",adjuvant,bDFS,"evaluated.
",7-18,days).,"96.9%,","91.7%,",83.5%,"low-,","group,",Late,(Common,Terminology,Criteria,Adverse,Events,v.4),follows:,gastrointestinal:,"(22%),","(7.2%),","3,",(0.36%);,genitourinary:,"(28.7%),",14,"(5%),",PSA,"(6.1%),",lymph,node,(1.4%),recurrences,detected.,Nine,(3.2%),deaths,"reported.
",Ultrahypofractionated,comparable,fractionation,GI,GU,"toxicity.
",Cajal-Retzius,transient,elements,developing,cerebral,cortex.,express,molecules.,"them,",heavy-chain,"neurofilaments,",construction,mature,"networks,",believed,feature,human’s,stain,SMI-32,non-phosphorylated,horizontally,oriented,soma,bipolar,labeled,layer,cats,0–2,DiI,"technique,",well-developed,vertical,branches,coming,horizontal,visualized,areas.,location,suppose,carnivores,share,primates,developmental,"corticogenesis.
","decades,",semiconductor,lasers,successfully,rhinology.,usage,nasal,swell,(NSB),barely,selection,NSB,970 nm,diode,reduction.,thermometric,wavelength,continuous,contact,2 W,10 W,step.,"cattle,",region.,experiments,temperature,"data,",4 W.,causing,thermal,damage,adjacent,improve,breathing,hypertrophy,vasomotor,rhinitis,NSB.,consisted,laser-turbinectomy,laser.,pathology,"laser-turbinectomy,",observation,respiration,anterior,rhinomanometry,subgroups,t-criterion,As,result,NOSE,scale,Student's,"t-test,",subjectively,noted,insufficiency,breathing.,indicates,"airflow.
",Trace,amine-associated,(TAARs),class,protein-coupled,biogenic,"amines,",products,decarboxylation,acids.,TAARs,(TAAR2-TAAR9),described,olfactory,epithelium,sensing,innate,odors.,members,"family,","TAAR5,",limbic,projection,emotions.,mouse,lacking,TAAR5,(TAAR5,"knockout,",TAAR5-KO,mice),beta-galactosidase,mapping,striatal,"metabolites,",GDNF,indicating,proliferation.,subventricular,"(SVZ),",subgranular,(SGZ),potentially,surrounding,ventricle.,neurogenesis,doublecortin,(DCX),proliferating,nuclear,(PCNA),SVZ,SGZ,"mice,",observations,emotional,transmission.,antagonists,exert,antidepressant,anxiolytic,opportunity,neurodegenerative,hemispheric,asymmetry,ERPs,low-frequency,oscillatory,hemispheres,stimuli,delayed,motion.,Event-related,read,books,choice,(passive,listening),indicated,trajectories,perceived,graphic,tablet,(active,listening).,goal,find,lateralization,right-hemispheric,"dominance,",contralateral,neglect,interhemispheric,asymmetry.,Apparent,dominance,hemisphere,ERSP,Stronger,contralaterality,left,corresponding,“neglect,model”,delta-alpha,oscillations.,Velocity,attention,consistently,interrelated,motion-related,single-trial,"measures.
",Antibodies,aquaporin-4,(AQP4),trigger,"cascade,",implicated,astrocyte,injury.,anti-AQP4,NMOSD.,"PREVENT.
","time-to-event,","trial,",1200 mg/2 weeks),"(2:1),",stable-dose,(IST),permitted,(except,rituximab,mitoxantrone).,Post,hoc,post,IST,demographic,"characteristics,",autoimmune,"comorbidity.
","region,","race,",historical,annualized,Expanded,Disability,Status,Scale,"score,",disorder.,regardless,"year,","disorder.
",Across,wide,apparent,"rate.
","(ClinicalTrials.gov).
",Carboxylated,"fullerenes,","particular,",tris-malonate,C60,"(C60[C(COOH)2]3,","CF),",great,interest,studying,"plants,",primarily,"malonate,",biological,means,improving,crop,yield,quality.,Impact,physiological,plant,state,enough.,"state,",netto,productivity,"salad,","tomatoes,",spring,"barley,",wheat,seed,germination,vegetative,plants,reasons:,absorption,assimilation,capacity,roots,aerial,parts,plants;,moisture,substances,organs;,entering,distributing,"organs,",physiologically,organic,"compounds,",cyclic,catabolism;,optimising,antioxidant,indicators,seedling,"condition,",solutions,CCF = 0.001–0.1,mg·dm−3,"plants.
",Approximately,worldwide,peritoneal,dialysis,practice,"globe.
","clinicians,","delivery,",Responses,88%,(n=160),313,(257,nephrologists,"[82%],",non-nephrologist,physicians,"[7%],",professionals,"[2%],",administrators/policy,makers/civil,servants,"[5%],",others,[4%]).,85%,(n=156),responded,questions,38.1,156,(19%),"questions,",Africa,(20/41),(15/22).,69%,modality,for≤10%,newly,failure.,1%,"costs,",(>75%),(out-of-pocket,expenses,incurred,patients),Asia,Average,exchange,volumes,adequate,(defined,3-4,exchanges,equivalent,automated,PD),72%,Low,makers;,explanations,underpinning,granular,data;,"data.
",Large,inter-,intraregional,disparities,"world,",greatest,"Asia.
",regimens,dydrogesterone,management,endometriosis-related,pelvic,"Observational,","months.
","Setting
",Twenty,gynecology,"Federation.
","Patient(s)
",fifty,endometriosis,"dysmenorrhea.
","Intervention(s)
",Dydrogesterone,mg,"daily,",5th,25th,menstrual,cycle,(prolonged,cyclical,regimen),continuously,(continuous,regimen).,cutoff,"Measure(s)
",Intensity,11-point,rating,(after,"months).
","Result(s)
",marked,–3.3,–3.0,"2.2,","respectively),","regimens,","pain,",analgesics,"required,","dysmenorrhea,","well-being,",health-related,quality-of-life,A favorable,"confirmed,",reactions,"Conclusion(s)
",dysmenorrhea,led,"well-being.
",Registration,"Number
","NCT03690765.
",Los,regímenes,de,tratamiento,didrogesterona,cíclicos,y,continuos,prolongados,son,efectivos,para,reducir,el,dolor,pélvico,crónico,en,mujeres,con,endometriosis:,resultados,del,estudio,"ORCHIDEA.
","Objetivo
",Comparar,la,efectividad,dos,diferentes,manejo,relacionado,"endometriosis.
","Diseño
",Estudio,cohortes,prospectivo,observacional,durante,seis,"meses.
","Entorno
",Veinte,clínicas,ginecológicas,Federación,"Rusa.
","Paciente(s)
",Trescientas,cincuenta,entre,años,edad,o,sin,"dismenorrea.
","Intervención(es)
",Didrogesterona,ó,veces,al,"día,",bien,los,días,25,ciclo,menestrual,(régimen,cíclico,prolongado),ininterrumpido,continuo).,Para,todas,las,pacientes,se,limitó,recogida,datos,meses,"tratamiento.
",Medida(s),resultado,"principal(es)
",Intensidad,una,escala,puntuación,numérica,puntos,(tras,"meses).
","Resultado(s)
",Se,observó,marcada,reducción,tanto,régimen,prolongado,como,continuo,(cambio,nivel,medio,desviación,estándar,"-3,3","2,2","-3,0","2,2,","respectivamente),",diferencia,significativa,ambos,grupos.,Con,"regímenes,",experimentaron,mejoras,significativas,intensidad,"crónico,",número,que,requirieron,"analgésicos,",severidad,"dismenorrea,",bienestar,parámetros,calidad,vida,relacionados,salud.,confirmó,un,perfil,seguridad,favorable,"didrogesterona,",informó,reacciones,adversas,severas,medicación,"estudio.
","Conclusión(es)
",demostraron,pronunciada,dismenorrea,resultaron,marcadas,todos,estudiados,"sexual.
",Novel,strategies,needed,optimise,surgical,resection,early-stage,(NSCLC).,atezolizumab,best,supportive,platinum-based,IMpower010,"randomised,","multicentre,","open-label,",done,227,sites,regions.,resected,IB,(tumours,≥4,cm),IIIA,Union,Internationale,Contre,le,Cancer,American,Joint,staging,(7th,edition).,(1:1),permuted-block,(block,four),(1200,days;,cycles,year),(observation,regular,scans,recurrence),(one,cycles).,"endpoint,","survival,",hierarchically,II–IIIA,whose,"(SP263),","population,",finally,intention-to-treat,(ITT),(stage,IB–IIIA).,care.,"ClinicalTrials.gov,",NCT02486718,"(active,","recruiting).
","2015,","19,","2018,",1280,resection.,1269,"chemotherapy,",1005,eligible,randomisation,(n=507),(n=498);,495,32·2,(IQR,27·4–38·3),(HR,0·66;,0·50–0·88;,p=0·0039),(0·79;,0·64–0·96;,p=0·020).,ITT,HR,(0·67–0·99;,p=0·040).,Atezolizumab-related,(11%),"(1%).
","cells,",Atezolizumab,offers,F,Hoffmann-La,Roche,"Genentech.
",Unnamed: 3122,Genetics,Buspirone-dependent,Abdominal,Pain,Transmission,Within,Nucleus,Tractus,Solitarius,"Rat,
",disease:,Reaction,(diaminocarbene)PdII,"complexes,
",region-specific,mellitus:,Opposite,"5-hydroxytryptamine,
",carcinomas,variants:,Effects,"mellitus,
",Brain,"motion,
",Cytochemical,"hepatocytes,
",anti-aquaporin-IgG-positive,disorder:,"extension,
",Estimation,"transform,
",system:,Biocompatibility,nanocomposite,Cyclooxygenase,mediate,Unmanipulated,Post-Transplant,Pediatric,"Leukemia,
",Suicide,trends,pandemic:,"countries,
",Addressing,barrier,drugs:,RCT,restores,patient-derived,"Parkinsonism,
",Practice,Patterns:,Survey,"Study,
",Graft-versus-Host,Prophylaxis,Bendamustine,Refractory,Dose-Ranging,Visual,"schizophrenia,
",Proton,Radiation,Treatment,Intermediate-Risk,Prostate,Cancer-5-Year,"Outcomes,
",labeling,feline,"cortex,
","body,
",trace,(TAAR5),knockout,Lateralization,motion:,"analysis,
",Benefits,Subgroup,"trial,
",Plant,Peritoneal,Dialysis,ORCHIDEA,Adjuvant,IB–IIIA,(IMpower010):,midbrain,periaqueductal,gray,(PAG),pain.,gut,inflammation-triggered,PAG.,PAG-executed,visceral,nociception,known.,c-Fos,immunohistochemistry,microelectrode,recording,colitis-induced,PAG,outflow,caudal,ventrolateral,medulla,(CVLM).,Analysis,inflamed,diminished,columns,"(CRD),",nonstimulated,subdivisions,Microelectrode,colitis-elicited,CRD-excited,unresponsive,weakened,CRD-inhibited,units.,Colonic,electrostimulation,CVLM,colitis.,ascending,injury-associated,hyperalgesia.,postinflammatory,stigmatized,face,accessing,ART.,natural,ART,1],2],165,ART-naïve,enrollment,andgeneralized,estimating,equations,"baseline,",12-,24-month,visits.,Logistic,initiation.,"gender,",CD4,"count,",(past,30-day),depressive,"symptoms.
",following:,(Q1;,Q3:,30;,37),30%,<350;,use.,31%,initiated,8.5,4.68;,13.61).,scores,yearly,0.57,"-1.36,",0.22).,(27/47,[57.4%]),initiate,Total,(AOR,"0.99,",95%CI,0.94–1.04;,AOR,"1.01,","0.96–1.05,","respectively).
","HIV-positive,","PWID,",alone,unlikely,Reducing,"barriers,","e.g.,",promoting,equal,substance-use,success,stigma-reduction,Alcohol,prevalent,hepatitis,C,Virus,(HCV),co-infection,alcohol's,harmful,Identifying,continued,unhealthy,interventions.,situational,motivational,HIV/HCV,co-infected,Guided,semi-structured,interviews,barriers,facilitators,abstaining.,Interviews,thematic,"approach.
",awareness,episodic,situations.,motive,triggered,stressful,"situations,",work-,family-related,conflicts.,friends,Women,endorsed,motives,motivated,stop,drinking.,Health,concerns,cited,reasons,drinking;,doctors,"abstain.
",Several,"identified,",opportunities,"prevention,",Awareness-raising,training,persons,"relatives.
",degrees,lockdown,world.,thoroughly,COMET-G,pertaining,"question.
",Material,gathered,online,questionnaire,"55,589",40,(64.85%,females,35.80 ±,13.61;,34.05%,males,34.90±13.29,1.10%,31.64±13.15).,Anxiety,"STAI,",depression,CES-D,suicidality,RASS.,Distress,probable,"respectively.
",Statistical,"Analysis
",calculation,Relative,Risk,"(RR),",Factorial,ANOVA,backwards,stepwise,"analysis
",two-thirds,lockdown.,1.72,1.90,psychiatric,6.88,"depression,",though,"small.
",reports,"findings,",suggestions,concerning,proactive,protect,vulnerable,"groups
",CE,CuSO4,2-hydroxypropyl-β-cyclodextrin,additives,background,electrolyte,pH 4.3,acids,lactic,"""healthy""",non-alcoholic,fatty,HepG2.,vitro,HepG2,oleate,palmitate,simulate,excessive,hepatocytes.,intracellular,triglyceride,"increased,",viability,decreased.,order,check,"pathology,",culture,medium,evaluating,repeatability,intermediate,precision,peak,migration,"times,",accuracy,(recovery,trueness,"method),",quantitation,limits.,proved,"sensitive,",reliable,accurate,concentrations,"Arg,","Ala,","Glu,",Gln,comparison,"control.
",Myeloperoxidase,"(MPO),",oxidant-producing,"neutrophils,",prime,immunothrombosis.,Native,MPO,"homodimer,",consisting,identical,protomers,(monomer),disulfide,bond.,But,"foci,",monomer,dimer.,Beside,"oxidants,",ultimately,ceruloplasmin,"(CP),","MPO,",Monomeric,(hemi-MPO),treating,dimeric,reductive,alkylation.,HOCl,molar,1:100,(MPO-HOCl).,surface-enhanced,Raman,(SERS),spectroscopy,peaks,510,526 cm−1,corresponded,recognizable,SERS-spectra,absent,hemi-MPO,intense,spectra,"MPO-HOCl,",cleavage,modification.,lesser,platelets,agonist-induced,aggregation,platelet-neutrophil,aggregate,formation.,CP,"HOCl,",monomeric,consequently,decreases,thrombosis,"foci.
",Moscow,"1950′s,",physicist,M.,Bongard,silent,dimensions,colour,vision,derive,colour-matching,whole,organisms,individual,channels.,"1956,",colleague,S.,Smirnov,extra-foveal,tetrachromatic,silent-substitution,called,‘replacement,colorimetry’.,steady,trichromatic,matches,"regions,",transients,visible,match,replaced,another.,"If,","primaries,",possible;,ones,chromatic,adaptation.,fourth,"rods,",long,discovery,intrinsically,photosensitive,fiftieth,anniversary,Bongard’s,grievous,"death,",translation,Smirnov’s,tetrachromacy,vision.,"commentary,",give,details,apparatus,briefly,reception,West,claims.,analogy,parafovea,‘weak,tetrachromacy’,heterozygotes,anomalous,"vision,","adaptation.
",Bipolar,(BPD),"cognition,",controversies,performance.,cognition,executive,"functions,","memory,",medication-naive,BPD,taking,olanzapine.,Forty-one,"controls,",unmedicated,drug-naive,olanzapine,performance,Flanker,"test,",Stroop,Corsi-block,test.,Bayesian,run,considering,maximum,robustness,avoid,bias,predict,worse,tasks.,dosage,"(i.e.,",effects).,pro-cognitive,carefully,interpreted,variables.,expect,helping,"researchers,",Predicted,pandemic.,picture,changing,vary,"timely,",pandemic's,"globally.
",public-sector,"countries/areas-within-countries,",searching,academic,contacting,custodians,necessary.,sent,request,22nd,June,2021,stopped,collecting,31st,October,2021.,(ITS),"sex-,",age-,sex-by-age,country/area-within-country.,nine,10-15,meta-regression,"variation.
","high-income,","upper-middle-income,",lower-middle-income;,"area(s)-within-the-country,",both).,greater-than-expected,countries/areas-within-countries,analysis;,"commonly,",lower-than-expected,numbers.,Certain,stood,"concerning,",countries/areas-within-countries.,"meta-regression,",explained,stringency,national,strategy.,Nor,income,ITS,lower-middle-income,fared,"well.
",Although,certain,sex-,age-based,"greater-than-expected,",minority.,Any,upward,place,alert,"continue.
","Abstract
",ALK-positive,histiocytosis,subtype,histiocytic,neoplasm,2008,infants,multisystemic,involving,entity,subsequently,occupy,wider,clinicopathologic,KIF5B-ALK,"remain,","date,",37,rearrangements.,phenotypic,"involvement,",originally,1A:,"6/39),",1B:,"10/39),",single-system,2:,23/39).,Nineteen,entire,(49%),neurologic,(7,Groups,1B,Histology,classic,xanthogranuloma,one-third,displayed,densely,"cellular,",monomorphic,appearance,lipidized,histiocytes,spindled,epithelioid,morphology.,Neoplastic,conferred,strong,phosphorylated,signal-regulated,"kinase,",MAPK,fusions,"CLTC-ALK,","TPM3-ALK,","TFG-ALK,","EML4-ALK,",DCTN1-ALK,Robust,durable,11/11,"inhibition,",involvement.,presents,landscape,guidance,emerging,"entity.
",Essential,(ET),practically,comprehensive,dedicated,"heterogeneity.
",differentiate,cluster,"clinical,","parameters.
",ET.,Clustering,"FTMS,","ADL,","MoCA,","Beka,",electromyographic,"IL-1β,","TNFα,",uric,"acid,","ceruloplasmin,","MDA.
","manifestations,",psychoemotional,adaptive,"pathogenesis,",homogeneous,clusters,"identified.
",Revealing,Implantation,electrodes,basement,vertebral,spinous,stably,fixed,cord.,"approach,",selectivity,transvertebral,(TS).,TS,forward,stepping,cat's,hindlimbs,epidural,"(ES).
",Materials,electrode,placed,VL3–VL6,vertebrae,decerebrated,cats.,ES,L5–L7,segments.,Kinematic,addition,musculus,(m.),iliopsoas,"(IP),",m.,tibialis,"(TA),",gastrocnemius,lateralis,(GL),"hindlimbs.
",VL3–VL4,"TS,",capable,bipedal,"stepping,",VL5,VL6,"animals,",Well-coordinated,intra-,coordination.,TS-induced,ES.,VL3,vertebra,lock,integer,Similarly,"model,",TS-evoked,site,specific.,They,VL4–VL5,(IP),VL5–VL6,"(TA,","GL).
",hypotheses,generators,lumbar,placement,surgically,easier,site-specific,neuromodulation,sensorimotor,investigating,"models.
",hormones,menopause,detrimental,woman's,mood,challenge,"gynecology.
","Aim
",peri-,postmenopausal,"women.
",methodological,scoping,reviews.,electronic,databases,Medline,"(PubMed),","Scopus,",Science,(WoS).,Publications,menopausal,review.,subject,records.,full-text,1986,2020,methodologies;,studies16,cross-sectional.,Investigations,addressed,domains,"implications
","practice,",appropriate,screen,If,woman,suffers,"either,",necessary,Strengths,reproductive,"subject,",small.,topic,clearly,"warranted.
",While,appears,"bidirectional,",(or,versa).,Future,dysfunctions,attitudes,"partners,","support,","sleep,",multiparity.,Azam,"Rahmani,",Elahe,"Afsharnia,",Julia,"Fedotova,",Shirin,"Shahbazi,",Arezoo,"Fallahi,",Leila,"Allahqoli,",Reza,"GhaneipoklGheshlagh,",Sarah,"Abboud,",Ibrahim,Alkatout.,Sexual,Function,Mood,Among,Menopausal,Women:,Scoping,Review.,J,Sex,Med,"2022;19:1098–1115.
",curative,Wiskott-Aldrich,(WAS).,Reported,respect,donors,predicting,poorer,outcome.,197,undergoing,2006,2017,Inborn,Errors,(IEWP):,(n,103),treosulfan,94),thiotepa.,post-HSCT,44.9,176,"alive,",resulting,88.7%,(GVHD)-free,(events,"failure,",GVHD),81.7%.,GVHD-free,(busulfan-,"treosulfan-based),",(matched,donor/matched,donor/mismatched,"donor),",(2006-2013,2014-2017).,<5,III,IV,extensive/moderate/severe,6.6%,"2.1%,",treosulfan-based,mixed,chimerism,frequently,(second,"HSCT,",unconditioned,"boost,",lymphocyte,"infusion,",splenectomy).,WAS,IEWP,"GVHD,","source,",≥5,tetrahydrobiopterin,(BH4),schizophrenia.,BH4,deficiency,precisely.,Objective:,loss,93,"BH4,","folate,",cobalamin,"(B12),","homocysteine,",C-reactive,"(CRP),",glutathione,(GSH),serum.Patients,psychopathological,examination.,folate,(p = 0.001,"p = 0.054,",homocysteine,(p = 0.012),moderately,(ρ = 0.43;,p = 0.0029),B12,p = 0.0020),inversely,(ρ = −0.54;,p = 0.00015),Cluster,biotype,"B12,",hyperhomocysteinemia.,CRP,GSH,"confirmed.
",noninvasive,tools,understand,states,"medications,",symptom,"severity,",low-level,"(CSF),","reliable,","robust,",approach.,purpose,(2),variables,diseases.,Fifty-six,(HCs;,age = 31.04,"years),",age = 32.84,"lithium,",age = 32.80,CSF,differed,discrimination,"mid-,",HCs.,exception,mediation,analyses.,aid,investigations,state-,trait-like,populations.,underscores,remediation,"interventions.
",article,PDT,HPV,elimination,"PDT
","retrospectively,",session,multi-course,depended,session.,Treatments,2015,Relapse-free,probability,Kaplan,Meier,estimator,elimiantion,"examined..
",82%,three-month,(R2 = 0.71).,90%,"0,8",(CI95%:,"0,53–1)",mild,(35.7%),(28.6%),leucocyte,demonstrates,CC,five-year,PDT.,completing,multi-treatment,invasive,achieve,intensive,non-interruptive,RALL-2009,fulfilled,auto-hematopoietic,T-cell,reliably,(DFS).,non-randomized,auto-HSCT,(ChT),only.,Aim:,appreciate,RALL-2006,protocol.,Patients:,RALL-2016,achieved,(CR),brought,randomization,informed,consent,ChT,267,Ph-negative,Dec,2016,Apr,2022.,"T-ALL,",74%,"male,",31.,5y,DFS,68%,"66%,",precursor,(ETP)-ALL,poor,"prognosis,",(PR),(52%,1st,CR).,87,(pts),randomized:,pts,"ChT,",44,auto-HSCT.,refused,auto-HSCT;,censored,refuse.,"arms,",went,allo-HSCT,mixed-lineage,(MLL),"leukemia,",Niimegem,MRD,persistence).,done.,patients:,7,conditioned,"iomustine,","etoposide,","cytarabine,",melphalan,(CEAM),Maintenance,1.5,HSCT.,Transplant-related,5%.,Landmark,"post-HSCT,",didn't,PR,"78%,",22%,ChT).,Auto-HSCT,induction.,persistence,(MRD-:,86%,81%,MRD+:,"40%,",auto-HSCT).,Conclusions:,auto-HCST,ETP-phenotype,prognostic,factor.,Addition,high-dose,consolidation,Medieval,yoga,texts,claim,special,exercise,muscles,"wall,","agnisara,",digestive,superior,(if,any),"agnisara.
",Ultrasound,volumetric,(SMA),performing,agnisara,carried,sexes,(8,"women).
","SMA,",systolic,diastolic,"velocities,","found,",contrasts,splanchnic,humans,physical,"activity.
",Properly,supply,gastrointestinal,successful,uncomplicated,hypertensive,"pregnancy,",definitions,"heterogeneous,",conflicting.,"pre-eclampsia.
",meta-analysis,Database,Reviews,date,"27,",thyroid-stimulating,"(TSH),","(FT4),",(TPO),"antibodies,",individually,"combination,","hypertension,","pre-eclampsia,",both.,Pregnancy,data.,multifetal,pre-eclampsia.,Individual-participant,logistic,sampling.,"PROSPERO,","CRD42019128585.
",1539,participate.,46 528,pregnant,"women,",39 826,(85·6%),sufficient,(TSH,TPO,status),classified,(3·2%),"hypothyroidism,",933,(2·3%),"hypothyroxinaemia,",619,(1·6%),"hyperthyroidism,",337,(0·8%),hyperthyroidism.,"euthyroidism,",pre-eclampsia,(2·1%,3·6%;,1·53,1·09–2·15]).,Subclinical,positivity,(p=0·0001).,U-shaped,quantify,"abnormalities,",adding,implications,defining,interventional,Arkansas,Biosciences,Institute,"Research.
",Cyclosporine,methotrexate,(MTX),(MSD),(allo-HCT).,"Recently,",(PTCy),registry-based,118,PTCy,1202,CSA/MTX,MSD,allo-HCT,leukemia.,matched-pair,(41.1%,21.3%;,P = .039).,+180,arms,(25.2%,25.4%,[P = .90],42.6%,"[P = .84],","Similarly,",(LFS;,54.4%,74.32%;,"P = .052),",(OS;,70.6%,79.7%;,"P = .15),",(GRFS;,38.1%,52.5%;,P = .49),arms.,"feasible,","GRFS,",conventional,MSD.,©,Cellular,Therapy.,Published,Elsevier,"Inc.
",Impaired,"colitis,
",lifetime,illicit,Russia–A,Situational,"co-infection,
",self-identified,gender,"anxiety,","study.,
",Cu2+,ions,Structure-biological,myeloperoxidase,"activation,
","vision,
","disorder,
",9-15,trends:,histiocytosis:,highlighting,"inhibition,
",Forward,Stepping,Evoked,Transvertebral,Decerebrate,"Cat,
","Review,
",Hematopoietic,syndrome:,EBMT,Tetrahydrobiopterin,schizophrenia:,Biochemical,"aspects,
",Correlates,Photodynamic,ALL-056,Intensification,Autologous,Non-Myeloablative,CEAM,Conditioning,Can't,Adults,T-Cell,Treated,Non-Intensive,Protocol:,Multicentral,Randomized,RALL,Yogic,"artery,
",pre-eclampsia:,Methotrexate,Matched,Sibling,Donor
0,ВСТРЕТИЛОСЬ_РАЗ_в_2020,30,1.0,229,1.0,2.0,20,4.0,6,332,4,367,5,317,1.0,1.0,3.0,4,9,7,2.0,37,12,4.0,1,3.0,3.0,3.0,3.0,1.0,18,4,33,3.0,4.0,11,13,3.0,1.0,9,3.0,83,2,2.0,1.0,3,4,2.0,2.0,1.0,13,4,4,22,2,10,1.0,1.0,1.0,1.0,1.0,2.0,1.0,35,1.0,1.0,1.0,2.0,2.0,4.0,20,1.0,3.0,4.0,6,68,1.0,1,1.0,3.0,27,1.0,13,2.0,2.0,7,1.0,1.0,1.0,2,2.0,1.0,76,9,6,1.0,1.0,1.0,7.0,1.0,56,1.0,12,2,4,1.0,1.0,5,2.0,1.0,2,6.0,1,1.0,1.0,1.0,1.0,1.0,3,45,7,8,5,1.0,2.0,1.0,4,12,1.0,1.0,2,1.0,2.0,2.0,6,7.0,1.0,1.0,1.0,1.0,1.0,5,123,2.0,1.0,15,3.0,1.0,7,3,1.0,4.0,1.0,4.0,1,3.0,31,3.0,22,16,5,1.0,7,1.0,1.0,5,1.0,5,16,24,85,1.0,2.0,3.0,1.0,1.0,1.0,1.0,1.0,10,3.0,3.0,3,1.0,2.0,2.0,1.0,8,1.0,6.0,1.0,2.0,1.0,1.0,8,3,17,2.0,1,7.0,1.0,3.0,9.0,2.0,2.0,1.0,2,1.0,1.0,1.0,137,1.0,1.0,2.0,1.0,11,12,1.0,4.0,1.0,1.0,6,1.0,7,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3,1.0,2.0,2.0,1.0,1.0,5,3,6,8.0,1.0,1.0,14,2.0,2.0,1.0,7,1.0,1.0,1.0,1.0,1.0,1.0,25,4,2,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,5,1.0,1,3.0,2.0,17,1.0,1.0,1.0,2.0,2.0,13,4,1,1.0,5,8,2.0,5,4,2.0,2.0,1.0,1.0,1.0,8,2.0,1.0,1.0,2.0,3,3.0,2.0,1.0,1.0,2.0,1.0,1.0,2.0,5,6,2.0,20,8,1.0,2.0,1.0,1.0,7,1.0,1,2,1.0,4,1.0,1.0,3.0,1.0,9,4.0,1.0,2.0,1.0,3.0,1.0,1.0,1.0,2.0,1.0,3.0,7,1.0,1.0,1.0,1.0,1.0,2.0,11,1.0,1,14,1.0,1.0,4.0,5.0,1.0,1.0,8,1.0,1.0,15,1.0,5,2.0,2.0,3,4,1.0,2.0,2.0,4,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,3.0,1.0,1.0,1.0,2.0,1.0,5.0,4.0,1.0,1.0,1.0,1.0,2.0,3.0,3.0,1.0,1.0,1.0,2,3,1.0,1.0,12,1.0,4,1.0,1.0,2.0,1.0,3,3.0,10,1.0,1.0,1.0,2,1.0,1.0,1,3,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,6,1,10,3.0,1.0,3,1.0,2.0,1.0,3,2.0,1.0,1.0,7,1.0,4,1.0,2.0,6,3,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,2.0,1.0,1,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,3,2.0,1.0,1.0,2.0,1.0,3.0,1.0,1.0,7,5,2.0,2,1.0,1.0,11,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1,2,1.0,1.0,3,1.0,1.0,1.0,1.0,3,1.0,1.0,7,1.0,1.0,3.0,1.0,1.0,1,1.0,1,2.0,1.0,2.0,2.0,2,1.0,2.0,1.0,1.0,1.0,1.0,7.0,1,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,7,1.0,1.0,1.0,1,1.0,1.0,6.0,1.0,5,1.0,1.0,2.0,3,2.0,1.0,1.0,1.0,4,5,1.0,1.0,6.0,1.0,1.0,1.0,1.0,8,1.0,2.0,4,1,13,5,6.0,3,5.0,5.0,2.0,3,55,2.0,2,1.0,1.0,1.0,2.0,8,2.0,2.0,7,1.0,1.0,1.0,1.0,2.0,1,2.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,6,3.0,8,3,13,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,8,4.0,1.0,1.0,2.0,1.0,5,1.0,1.0,2.0,1.0,2,4,1.0,2.0,14,4,1.0,1.0,1.0,5,19,9,1.0,3.0,1.0,1.0,1.0,1.0,10,2,1.0,1.0,1.0,4,2.0,1.0,1.0,6.0,1.0,4,1.0,1,3.0,13,1.0,4,9,4,1.0,1.0,1.0,3,1.0,3.0,5.0,1.0,1.0,1.0,4.0,2.0,1.0,3,1.0,2.0,1.0,1.0,1.0,1.0,1.0,3,9.0,1,3.0,3,4,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,4,1.0,1.0,1,2,1.0,3.0,6,1.0,1.0,2,2.0,3.0,4,4,1.0,3.0,1.0,1.0,3,4.0,1.0,3.0,1.0,4,1.0,2.0,1.0,1.0,4.0,1.0,2,3.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,11,1.0,2,1,1.0,1.0,2.0,1.0,1.0,1.0,4,1.0,2.0,5.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,10,4,3,8,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,7,1.0,1.0,1.0,1.0,1,1.0,1.0,1.0,3.0,2,2.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1,2.0,1.0,7,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1,3.0,4,2.0,2.0,7,2.0,1.0,2.0,1.0,3.0,5.0,5.0,2.0,7,9.0,1.0,1.0,1.0,2.0,3,1,1.0,3,5,5,1.0,1.0,1.0,1.0,1,3,1.0,5,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,4.0,4.0,1.0,1.0,2.0,4,1.0,1.0,1.0,1.0,3,1.0,2.0,1.0,1.0,1.0,19,1.0,1.0,2.0,11,3,1.0,1,5,1.0,1.0,1.0,1.0,1,2.0,1.0,2,1.0,1.0,2.0,4,4.0,4.0,2.0,2.0,3.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1,1.0,1.0,3,2.0,1.0,2.0,5,6,1.0,1.0,1.0,6,4.0,1.0,3.0,1.0,2.0,1.0,2.0,1.0,2,2,1.0,1.0,1.0,4,1.0,2.0,1.0,1.0,5.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,3.0,3.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1,5,1.0,1,4,2.0,1.0,1.0,2.0,1.0,2,1.0,2.0,1.0,2.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,3,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,5.0,2.0,1.0,2.0,1.0,2.0,3.0,2.0,1.0,1.0,1.0,1.0,1.0,3,1.0,1.0,1,1.0,1.0,1.0,2.0,3.0,2.0,1.0,1,1.0,6,4.0,1.0,1.0,1.0,1.0,2.0,2,1.0,2,1,1.0,1.0,2.0,1.0,2,1.0,6,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2,1.0,1.0,2.0,1,1.0,3,2.0,1.0,1.0,1.0,9,4,2.0,2.0,1.0,5.0,2.0,1.0,1.0,3.0,2,2,1.0,1.0,1.0,4,1,1.0,4,3,1.0,2,2.0,3,1.0,2.0,5,2.0,1.0,1.0,2,1.0,1.0,1.0,1.0,5.0,7,3.0,2.0,3.0,1.0,1.0,1.0,1.0,3.0,8,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,5.0,2.0,2.0,2.0,2.0,3,1.0,2.0,5,1.0,4.0,1.0,1.0,1.0,1.0,8,1.0,1,2,3,1.0,2.0,1,2.0,1.0,1.0,2,1.0,1.0,4,1.0,2,1.0,1.0,4,1.0,1.0,5.0,1.0,5.0,1.0,1.0,1.0,1.0,1.0,4.0,8.0,2.0,4,1,2.0,2.0,1.0,1.0,3.0,2.0,1.0,2.0,1.0,3,7.0,2.0,2.0,1.0,2.0,1,5,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2,1.0,2.0,1.0,1.0,1.0,5.0,3.0,3.0,2.0,1.0,1.0,1.0,1.0,8,1.0,1.0,1,1.0,3.0,2.0,1.0,1.0,1.0,2.0,2.0,2,2,1,1.0,1,1.0,2.0,3,1.0,2.0,2.0,1.0,1.0,1.0,1,5,1.0,1.0,1.0,1.0,1.0,1.0,4.0,15.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,3,5,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,3,3.0,5.0,5.0,2.0,2.0,3.0,2.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,2.0,2.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1,2,1.0,1.0,1,1.0,1.0,1.0,1.0,1.0,2,2.0,1.0,1.0,1.0,1.0,3.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,2,4,1.0,1.0,1.0,12,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,5.0,8.0,3.0,1.0,6.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1,9,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,3,1.0,1,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,7.0,1.0,1.0,1.0,1,1.0,1.0,1.0,1.0,1,1.0,1.0,1.0,1.0,1.0,1,1,2.0,1.0,1.0,1.0,2.0,1.0,1.0,3,2,2,1.0,1.0,1,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,2.0,1.0,4.0,3.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,9,1.0,1.0,1.0,1.0,1.0,7,5,1.0,1.0,1.0,1.0,1,1.0,1.0,1.0,1,1.0,1.0,1.0,2,1,3.0,1.0,3,1.0,5.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4,1,2,1,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2,1.0,1.0,4,1.0,1.0,1.0,1.0,2,1.0,1.0,1.0,1.0,2,1.0,2.0,2.0,1.0,2.0,1.0,2.0,2.0,3.0,2.0,1.0,1.0,1,1.0,6.0,1.0,1.0,1.0,1.0,1.0,2,3.0,11.0,3.0,3.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,3.0,2.0,1.0,2,1.0,1.0,1.0,1.0,1.0,1.0,1,3.0,1.0,2.0,1,15.0,2.0,1,1.0,1.0,2.0,1,1.0,7,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,7,1.0,2.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,6.0,1.0,1.0,2,1.0,2,1.0,2.0,3.0,1.0,1.0,2.0,2.0,2.0,1,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,8.0,1,7.0,8,1,4.0,1.0,2.0,1.0,1,1.0,1,1,1.0,7.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,3,13,1.0,1,10.0,1.0,1.0,2.0,1.0,3.0,3.0,1.0,1.0,3.0,1.0,1.0,1.0,4.0,2.0,2,3.0,3,2.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1,2.0,1.0,4.0,2.0,1.0,1.0,1.0,2.0,1.0,3.0,1.0,1.0,1.0,1.0,1,2.0,2.0,1.0,1.0,5.0,1.0,1.0,3.0,1.0,6,3.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,5,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,2.0,2.0,1.0,1.0,1.0,2.0,2.0,2,5,2.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,4.0,2.0,1.0,2.0,3.0,2,3,1.0,1.0,2.0,3.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1,2.0,2,1.0,1.0,1.0,1,2.0,1.0,2.0,4.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1,2.0,2.0,1.0,1.0,1.0,5.0,2.0,1.0,1.0,3,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,2,1.0,4.0,1.0,1.0,2,1.0,2.0,1.0,1.0,1,1.0,1.0,1,2,1.0,1.0,1.0,2.0,1.0,1,1.0,1.0,1,1.0,1.0,8.0,10.0,2.0,3,6.0,3.0,1.0,1.0,3.0,1.0,4.0,1.0,3.0,1.0,1.0,2,4.0,9,1.0,1.0,1.0,3.0,3.0,2.0,1,1.0,1.0,2.0,3.0,1.0,1,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1,3,2.0,1.0,1.0,1,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1,1.0,3.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1,1.0,1,2.0,1.0,3.0,1.0,1.0,1.0,3.0,1.0,1.0,1,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1,1.0,1.0,1.0,1.0,1.0,1,1.0,1.0,1.0,1.0,4.0,3.0,1.0,3.0,1.0,7,4.0,2.0,1.0,2.0,1.0,2.0,7.0,1.0,1.0,1,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2,4.0,2,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,2.0,2.0,2.0,1.0,1.0,1.0,1.0,2,1.0,1,1.0,1.0,1.0,1.0,1.0,1,1.0,1.0,1.0,2,1.0,1.0,3.0,3,1.0,1.0,1.0,1.0,1,1.0,1.0,1.0,1,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,2,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,4.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,2.0,3,1.0,2.0,1.0,1.0,1.0,1,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,2,2.0,1.0,2.0,3.0,1.0,1.0,2.0,1.0,2,1.0,1.0,2.0,1.0,3,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,3.0,1.0,3,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,3,7.0,3,1.0,2,1.0,2.0,1.0,1.0,1.0,1.0,1,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,4.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1,3.0,2.0,2.0,3,1.0,1.0,3.0,3.0,1.0,2,3.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1,4.0,3.0,13.0,1.0,1.0,1.0,1.0,1,1.0,1,1.0,1.0,2.0,2,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2,1.0,1.0,1.0,1.0,1.0,1.0,1.0,7.0,2.0,4,4,2.0,2.0,2.0,2,1,2.0,1.0,1,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,7.0,1.0,2,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,3,1.0,4.0,1.0,4,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1,1.0,1.0,1.0,1.0,1.0,1,2.0,1.0,1.0,2.0,2.0,2.0,2.0,1.0,1.0,2,3.0,1.0,1.0,1.0,1.0,1.0,1.0,2,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,4.0,5,1.0,1.0,1.0,1.0,2.0,2.0,1,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2,1.0,1.0,1.0,1,3.0,1.0,1.0,1.0,2.0,4.0,1,1.0,4.0,3.0,1.0,1.0,1.0,1.0,1.0,1,1.0,1.0,1.0,2.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1,1.0,1,1.0,1.0,3.0,6,6,4.0,2.0,2.0,1,1.0,1.0,3.0,4.0,2.0,5.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,3,1.0,2.0,1.0,3.0,2.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1,1.0,2,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1,1.0,1.0,1.0,5.0,1.0,8.0,6.0,1.0,1.0,1.0,2.0,6.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,6,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2,1,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1,1.0,1.0,1.0,1.0,1.0,1,2.0,1.0,4.0,1.0,1,1.0,4.0,2.0,1.0,1.0,1.0,1,2.0,1.0,1.0,4.0,5.0,1,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1,1.0,1.0,3.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2,1.0,1.0,1.0,1,2.0,2.0,2.0,1.0,1.0,1,6.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,2.0,2.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1,1.0,1.0,2.0,2.0,2,1.0,1.0,2,1.0,2.0,1.0,1.0,1.0,1.0,1,1.0,2.0,2,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1,1.0,1.0,3.0,1.0,1.0,1.0,3.0,3.0,1.0,2.0,5,2.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1,5.0,3.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2,1.0,1.0,1.0,1.0,2.0,1.0,1.0,3.0,1.0,1.0,1.0,1,2.0,1,1.0,2.0,1.0,1.0,1.0,1.0,6.0,1.0,1.0,1.0,1.0,1.0,1,4.0,1.0,1,2.0,3.0,1.0,1,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1,1.0,1.0,1.0,1.0,1.0,1.0,1,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2,2,1.0,3,1,1.0,1.0,2.0,2,2.0,2.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1,1.0,1.0,1.0,1.0,1.0,1,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
0,ВСТРЕТИЛОСЬ_РАЗ_в_2021,31,,263,1.0,,24,,1,382,2,359,3,294,,,1.0,3,4,12,,42,8,,3,,,,5.0,,21,3,31,,,4,5,1.0,,7,,70,4,,,7,1,,,1.0,17,4,3,14,1,12,,,,,,1.0,,45,,,,,,,12,,,,5,88,1.0,2,,,27,,19,,,10,3.0,1.0,1.0,1,,1.0,70,13,6,,,,1.0,1.0,61,,7,1,6,,,7,,,1,3.0,8,,,1.0,,,1,32,9,11,3,,,,6,12,2.0,,1,,,,2,3.0,,,,,2.0,3,124,,,10,,,12,2,1.0,6.0,,1.0,3,,28,,19,20,5,,11,,,1,,3,22,25,92,,,,,3.0,,,,9,,,2,,,,,3,,5.0,1.0,,,,12,3,9,4.0,1,,,,5.0,,,,3,,,,140,,,,,1,8,,,,,3,,9,,1.0,1.0,,,,,1.0,2.0,9,4.0,,,,,5,6,6,8.0,,,16,,,,7,,,2.0,,,,22,5,2,,,4.0,,,,,,,2,,1,,,17,,,,,,9,1,3,,8,13,,1,7,,,,,,3,,,,,4,4.0,,,,,,,1.0,17,4,,35,7,,2.0,,1.0,7,,2,5,,1,,1.0,7.0,,7,2.0,,,,,,,,,,,4,,,,,,,8,,2,19,,1.0,,,,,9,,,8,,10,,1.0,4,3,,,,4,,,,,,,,,,,,,,1.0,,,,,,,,,,,,,,2,1,,,13,,12,,,,,2,,13,,,,3,,,1,2,,,,,,,,,,8,1,4,,,1,,,,2,,,,7,,3,1.0,,2,1,,,,1.0,1.0,,,,,1.0,1,,,,,1.0,,,,5,1.0,,,,,6.0,,,4,5,1.0,4,1.0,,7,1.0,1.0,1.0,,,1.0,,3.0,,1.0,,,,2,1,,,4,,3.0,,,6,,,1,,1.0,,,1.0,1,,1,1.0,6.0,,3.0,1,,,,,,3.0,,8,,,,,,,,,,,4.0,,6,,,,1,1.0,,1.0,,11,1.0,,,1,,,,,4,4,,1.0,5.0,,,,2.0,3,1.0,,3,2,7,3,,3,4.0,2.0,,1,83,,1,,2.0,,,2,,,3,1.0,,,4.0,1.0,1,1.0,,,,,,,,,3,,5,1,10,,,,,,,,,3.0,,,4,1.0,,,,,4,,,,,1,9,,,12,5,,,,1,3,8,,,,,,1.0,10,3,,,,4,1.0,,,,,6,,1,,19,,6,5,7,,,,2,,,3.0,,1.0,,,,1.0,1,,1.0,,,,,,4,,2,,3,8,,,,,,1.0,,,,,,,1,,,3,3,,5.0,6,,,3,2.0,,2,1,,,,,1,5.0,,,,8,,,,,,,2,,,,,1.0,,,,,5,,1,1,,,,,1.0,,3,,1.0,1.0,,,,,,,,,,,1,,,,,,,,,6,7,7,4,,,,,,,,,,,,,,,,7,,,,,1,,,,,3,1.0,,,,,,,,,,,,,,3,,,3,,,,,,,,3,,,,1.0,,,,,,,,2,3.0,2,1.0,1.0,1,,,,,,,,,5,2.0,,,,,3,1,,9,5,6,,,,,2,3,,2,1.0,,1.0,,,,,,,1.0,,,,,,,,,,4,,,,,3,1.0,1.0,,,,12,,,1.0,5,1,,1,2,,,,1.0,1,2.0,,2,1.0,,1.0,6,,,,,,,,2.0,,1.0,,3.0,,1,1.0,,2,,2.0,,9,6,2.0,,,2,2.0,,,,,,,,3,3,,,,7,,1.0,,,,,,,,1.0,5.0,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,,,,,,,,,,,,,,3,3,,1,2,,,,,,1,,,1.0,,,,,,,,,,2.0,,,1.0,,,,1,,,,1.0,,,,,,,,,,,,,,2.0,,,2.0,,,,,,,,,,,,10,,,1,,,1.0,8.0,1.0,,,1,,8,,1.0,,3.0,,,2,,1,2,,,,2.0,5,,5,,,1.0,,1.0,,4.0,4,,,,3,,2,,1.0,,,9,1,,,,4.0,,,,1.0,1,1,,,,2,2,,2,2,,12,1.0,4,,,2,,,,2,,,,,,2,,,4.0,,,,,,3,1.0,,,,,,,,1.0,5.0,,,,,2,1.0,,2,,,1.0,,2.0,,8,,2,1,4,,,1,,,2.0,5,,,3,,2,,,2,,1.0,,,,,5.0,1.0,,,4.0,,,3,3,,,,,,,,,,1,2.0,,,,,1,2,,1.0,,,,,,,,,6,,,,,,4.0,2.0,4.0,3.0,,,,1.0,8,,,3,1.0,,,,,,1.0,,3,3,2,,3,4.0,4.0,3,,1.0,,,,,5,3,,,,1.0,1.0,,,,,1.0,,,,,,4,14,,,,,,,1.0,,,,,,,5,,2.0,,,,,,,2.0,,,,,,,1.0,1.0,,,3.0,,4.0,,,,,,,2,4,1.0,,2,,,,,,1,,,1.0,,,,,1.0,,,,,,,,1.0,2,1,,,,12,,,,,,,,,,,,2.0,,,,,,,,,,,,,3.0,,,,,1.0,,1.0,,,,,,3,9,,,,,,,,,2,,,,1.0,,,,,,1.0,,1,,1,,,,,,,2.0,,,,,,,,,,1,,,,,1,4.0,,,,,1,2,,,1.0,,,1.0,,1,1,1,,,1,,,,2.0,2.0,,,,,1.0,2.0,,,,2.0,,2.0,,,,,,1.0,1.0,,,,,,1.0,,,,10,,,,,,8,11,,,2.0,,1,1.0,,,1,,,,3,1,5.0,,2,,,,,,,,,,,,,,1.0,,11,2,4,3,,1.0,,,,,,,2.0,1.0,,,,,,1,,1.0,2,,,,,2,,,,,5,,1.0,,,,,,,,2.0,,,2,2.0,,,,,,,4,,1.0,3.0,,,,,,,,,,,,,1.0,1.0,4,,,,,,,4,1.0,,,1,22.0,3.0,1,,,,1,,1,,,,,,,1.0,,,5,,,,,,,2.0,,,,,1.0,4,1.0,2,,,2.0,,,,2.0,6.0,7,,1.0,,,,,,,18.0,,2.0,2.0,,6,,9,11,,,,,2,,2,3,,2.0,,,,,,,,,,,,3,8,,3,2.0,,,,,3.0,,,,,,3.0,,1.0,,1,,4,,,,,,1.0,,,1,,1.0,,,,,,,,,,,,,1,2.0,1.0,,,1.0,,1.0,,,4,4.0,,,,,,,,,,4.0,,2,,,,,,,,,,,,,,,,2.0,,2.0,,,1.0,,1.0,1.0,1,2,,1.0,1.0,,,,,,,,,,,2,6,,,1.0,,,,,1.0,,,,,,,,,,2,,1,,,,2,,,,,1.0,,,,,1.0,,,1.0,,,2,2.0,,,,,,1.0,,,4,,,,,,,1.0,1.0,,,,2.0,3.0,,,,1,,,1.0,,1,,,,,5,,,1,1,,,,,,7,1.0,2.0,1,,,,,,2,,,1.0,,,,,,,,1.0,2,,2,,,1.0,,,,2,,,,,,1,,,,,,,,,,,,,,1.0,1.0,2,2,,,,2,,,,,,,,,,,,,,,,,3,,,,,,,,,,,1,,,4.0,,,,,2,,1,,,,,,,,,,1,,,,,,,,,1,,,,,,4,,,,,,,,,,7,,,,,,,5.0,,4.0,2,,,,,,,,,1,,1,,,,,,1.0,,,,,,,,,,,,,3.0,,,,,,3.0,,,,,,2,,3,,,,,,2,,,,8,,,,3,,1.0,,,1,1.0,,,2,,,,,,,1.0,,,1,,1.0,,,,,5.0,,,1.0,,,,,,1.0,,1.0,,,3,,,,,,4,1.0,1.0,,,,,,,,5.0,5,,,,,,,,,1,,,1.0,,4,,,,,,,,,,1.0,,,,,,,,,,,,,5,1.0,1.0,4.0,,,,,1.0,,,,,,1.0,3.0,1.0,,,,,,,,,1.0,,2.0,,,,4.0,,,,,2,,2,,3,,,,,,2.0,2,,,1.0,,1.0,,1.0,,,,,,,2.0,1.0,,10,,1.0,,7,,,,,,1,,,1.0,,,,,3.0,,,,,,2.0,,1,1.0,,3.0,,,,1.0,6,,1,,,1.0,1,2.0,,,,,,,,,,,1.0,,,1.0,,,2,,,,,,,,,,2,1,,,,8,2,,,2,,,,,,,,,,2.0,,2,1.0,,,,,1.0,,,,,,,,,,,,,,,,,,,,3,,,1.0,5,,,,,,,,,,,,,,,1.0,,,,,,,,,1.0,,1.0,,1,,3.0,,,,6,1.0,,,,,,,,,1,,,,,,2.0,1.0,1,,1.0,,,,,,,1.0,,2.0,,1.0,,,,3.0,,,,,,,,,,,,,,,,,,,,,,,,,6.0,2.0,1.0,,1.0,,,,,,,,,,,2.0,,1.0,,,,,1,,,,1.0,,,3,,,,2.0,,,3.0,,,6.0,,,,,,5,1.0,1.0,,5,,,,,,,12,,,,1.0,2.0,,1.0,,2,,,,,1.0,,2.0,,1.0,,3.0,,,4,,2,,,2.0,1,1,,,,1,,,,,,,,,,,,,,,,,,,,,,,,4.0,11,,,,,,,,,,,,,,,,,1,,3,,2.0,,,,2.0,,,,1.0,,,,,1,3.0,,,,,,3.0,,,,,1.0,,,,2.0,,,,,,,,,,,,,,,,,,,,6,,,,,,1.0,,,,,,,,,4,1,,,,,,,,,,,1,,,,,,,,1.0,,,,,,,1.0,,1,,,1.0,4.0,1.0,1,2.0,,3.0,,2,,2.0,2.0,,,,1,,,,,5.0,1,,,,,,,1.0,,,,,3,,,,,,,,,,,,1.0,,2.0,,,,,1,4.0,,,,,,,5,,,,,,1.0,1.0,4,,,,1,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,6,,,,,3,,,2,,,,,,,2,,,1,,,4.0,,,3.0,,,1.0,,1.0,,3.0,,,,,,1.0,,,,,,,,,,1,,,,,,,,,,1,,,,,,,,,,3.0,11,,1.0,,,1.0,,,,,,,2.0,,6,1.0,1.0,,,,,,,,,,,,6,,,,,3.0,,,,,,,2,,1,,3.0,1.0,3.0,,,,,,,,,4,4.0,,2,2.0,,,1,,,,1.0,,,1.0,,1.0,3.0,,1.0,,,,,,,,,1.0,,,,,,,,,,,,,,,2,,,,,,,1,,,,1.0,1.0,,,,,1.0,,,1,2.0,,,,,,,,1.0,1.0,,2.0,,,,,,,,,,,1.0,1,1,,2,1,1.0,,,2,,,,,,1.0,,,2.0,,,1.0,,1.0,,2.0,,,,,,,,,,,,,,1.0,,1.0,,2,,,,1.0,,,,,,,,,3,,,1.0,,1.0,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,1.0,1.0,1.0,8.0,1.0,7.0,1.0,1.0,1.0,1.0,7.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,2.0,5.0,1.0,1.0,4.0,2.0,1.0,1.0,1.0,4.0,1.0,2.0,1.0,1.0,1.0,1.0,4.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,5.0,1.0,2.0,1.0,1.0,2.0,3.0,6.0,1.0,4.0,1.0,1.0,1.0,4.0,4.0,2.0,1.0,1.0,1.0,1.0,6.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,5.0,8.0,2.0,3.0,7.0,1.0,1.0,5.0,4.0,2.0,1.0,1.0,2.0,2.0,2.0,3.0,1.0,1.0,1.0,1.0,2.0,7.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,8.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,5.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,4.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,2.0,5.0,1.0,2.0,3.0,2.0,2.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,7.0,10.0,2.0,1.0,3.0,1.0,1.0,1.0,1.0,4.0,4.0,1.0,3.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,3.0,1.0,1.0,1.0,5.0,5.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,2.0,1.0,4.0,2.0,1.0,4.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,2.0,1.0,3.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,2.0,1.0,3.0,2.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,2.0,1.0,1.0,5.0,4.0,4.0,2.0,1.0,3.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,3.0,1.0,1.0,1.0,1.0,3.0,1.0,2.0,3.0,3.0,3.0,2.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,3.0,2.0,5.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,2.0,4.0,2.0,2.0,2.0,1.0,1.0,5.0,2.0,1.0,9.0,6.0,2.0,2.0,6.0,1.0,3.0,2.0,2.0,3.0,2.0,1.0,2.0,2.0,3.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,4.0,3.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,2.0,1.0,1.0,2.0,1.0,1.0,8.0,1.0,1.0,1.0,1.0,5.0,5.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,2.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,2.0,1.0,3.0,1.0,1.0,1.0,1.0,2.0,3.0,1.0,3.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,2.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,3.0,6.0,1.0,2.0,2.0,2.0,4.0,4.0,4.0,2.0,10.0,2.0,3.0,10.0,1.0,1.0,2.0,5.0,3.0,1.0,1.0,14.0,2.0,4.0,1.0,1.0,1.0,2.0,1.0,2.0,6.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,2.0,2.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,5.0,3.0,2.0,3.0,2.0,1.0,3.0,1.0,1.0,2.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,5.0,1.0,3.0,7.0,2.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,4.0,4.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,5.0,1.0,1.0,1.0,3.0,1.0,6.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,3.0,2.0,1.0,1.0,2.0,2.0,1.0,1.0,2.0,3.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,4.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,6.0,2.0,1.0,2.0,22.0,5.0,2.0,3.0,1.0,1.0,1.0,3.0,2.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,2.0,2.0,4.0,3.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,5.0,2.0,2.0,1.0,1.0,5.0,1.0,1.0,1.0,4.0,2.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,4.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,7.0,1.0,1.0,3.0,2.0,3.0,1.0,3.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,2.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,6.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,4.0,2.0,1.0,5.0,5.0,4.0,9.0,1.0,2.0,2.0,2.0,2.0,1.0,3.0,2.0,1.0,1.0,2.0,2.0,2.0,2.0,2.0,1.0,1.0,2.0,2.0,2.0,2.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,5.0,2.0,7.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,7.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,2.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,3.0,4.0,6.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,5.0,1.0,5.0,1.0,2.0,1.0,1.0,3.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,2.0,2.0,1.0,1.0,2.0,1.0,10.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,5.0,2.0,1.0,1.0,1.0,8.0,4.0,4.0,1.0,2.0,1.0,4.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,6.0,1.0,1.0,3.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,2.0,3.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,2.0,1.0,3.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,3.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,4.0,1.0,1.0,7.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,3.0,26.0,5.0,3.0,1.0,12.0,1.0,2.0,1.0,1.0,1.0,1.0,5.0,7.0,7.0,6.0,9.0,2.0,8.0,2.0,1.0,6.0,1.0,1.0,1.0,1.0,9.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,3.0,2.0,1.0,1.0,1.0,2.0,3.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,2.0,2.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,7.0,6.0,6.0,2.0,3.0,2.0,2.0,2.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,6.0,3.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,2.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
0,ВСТРЕТИЛОСЬ_РАЗ_в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
